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Prenatal substance exposure such as alcohol, nicotine, and opiates is known to 
modulate autonomic regulatory function during sleep, and to decrease arousability and 
spontaneous movements (SM). SM during sleep may reflect a protective mechanism for 
immature patterns of arousals. Neurodevelopmental compromise in sleep and arousal 
systems may underlie sudden infant death syndrome (SIDS) risk in which infants expire 
during sleep. Previous studies from our laboratory found abnormal patterns of neonatal 
arousal, sleep fragmentation, and deficits in sleep-related SM in infants with prenatal 
alcohol exposure. In this study, prenatal exposure to methadone was hypothesized to 
disrupt the development of sleep and arousal neural circuitry, which have been found for 
other high-risk samples. Neonatal Abstinence Syndrome (NAS) is a common 
consequence of prenatal methadone exposure that may appear within 24 - 72 hours post-
birth, and is known to disrupt sleep due to hyperarousability. As a secondary hypothesis, 
the neonatal age (day 1 or 2 of life) was expected to affect infant sleep and arousal 
outcomes in methadone-exposed neonates particularly on day 2 when NAS symptoms 
increase. Additionally, single nucleotide polymorphism (SNP) in the catechol-O-methyl-
transferase (COMT) gene was found to associate with the severity of NAS in our previous 
study. NAS severity has been associated with sleep disorders. Therefore, the second 
hypothesis of this thesis study is that the minor allelic variants (AG/GG) of the COMT 
gene previously identified as protective of NAS severity may also associate with better 
sleep organization and more robust SM than the carriers of the AA genotype. Rural, 
disadvantaged Caucasian mothers and infants (N=58 dyads: methadone=37, 
comparison=21) were recruited from multiple narcotic treatment sites and prenatal clinic 
at Eastern Maine Medical Center (EMMC). Mothers were interviewed to determine 
demographics, psychiatric status, and substance abuse history during the 3rd trimester. Bi-
weekly maternal urinalysis screens and neonatal meconium were applied to verify co-
morbid alcohol, tobacco, and other drug use. Finnegan scores determined symptoms of 
withdrawal in opioid exposed newborns. Videosomnographic recordings of behavioral 
states were collected in the newborn nursery of EMMC overnight, and recordings 
between 2400-0500h were analyzed for frequency and duration of sleep, wake, arousal, 
and SM. Saliva samples for genetic study was collected using OrageneTM kits. Results 
from behavioral state analysis (n=50) showed that methadone-exposed neonates were 
significantly hyper-aroused and crying more on both day 1 and 2 of life (p<.05); and both 
the frequency and duration of these parameters increased significantly in the methadone-
exposed neonates on day 2 of life, as expected. In the genetic study (n=20), neonates with 
NAS protective AG/GG genotypes showed better behavioral sleep, fewer arousals, and 
robust SM than infants with NAS risk AA genotype (p<.05). These findings support 
evidence of sleep fragmentation in the exposed neonates that is exacerbated by the 
passage of time since birth when withdrawal symptoms compound the intensity of sleep 
disturbance and infant distress.  Consistent with other findings from other SIDS-risk 
samples, these findings indicate that arousal and SM regulation may be disrupted in 
methadone-exposed neonates, suggesting that prenatal methadone may increase risk for 
SIDS.  
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CHAPTER 1 
INTRODUCTION 
Misuse of prescription opiates such as Oxycontin, Percocet, and Vicodin has 
increased in the past decade and is alarming because a high percentage of the opiate 
dependent population consists of women of childbearing age (i.e., 18 to 34 years old) 
which has resulted in a sharp increase in the number of newborns with prenatal opiate 
exposure (Office of National Drug Control Policy, 2011). These newborns are at high risk 
for developing neonatal abstinence syndrome (NAS), which is a marker for stress 
abstinence likely to surface within 24 to 72 hours postpartum (Jones, Kaltenbach, Heil, 
Stine, Coyle et al., 2010). Maine is identified as one of the states with the highest opiate 
addiction, according to a recent report by the Substance Abuse and Mental Health 
Services Administration (SAMHSA, 2012), thus making the prescription opiate abuse a 
major concern of the state of Maine. Our laboratory has investigated pregnancy and early 
development of methadone-exposed infants born in Maine by assessing cognition and 
learning (Logan, Hayes, Brown, Tisher, Paul, & Krishnan, 2009), maternal depression 
and infant temperament (Heller, 2012), variations in the degree of NAS in relation to 
maintenance therapy type (Pritham, Paul, & Hayes, 2012) and genetics (Wachman, 
Hayes, Brown, Paul, Harvey-Wilkes et al., 2013). This thesis study will investigate signs 
of potential neural circuitry deficits in utero by analyzing the sleep-wake continuity and 
arousal regulation of methadone-exposed neonates within the first 2 nights of life before 
NAS appears. 
NAS is characterized by central nervous system (CNS) hyperirritability and 
dysfunction in the autonomic nervous system, gastrointestinal tract, and respiratory 
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system, and one major characteristics of this condition is sleep disruption due to 
hyperarousability (Finnegan & Kaltenbach, 1992). Proper sleep regulation is essential 
especially during the neonatal period when maximum neural proliferation or expansion of 
neural network occurs, particularly during rapid eye movement (REM) sleep (Mirmiran, 
Maas, & Ariagno, 2003). An infant’s inability to maintain sleep quality has been 
associated with sudden infant death syndrome (SIDS) (Kinney, 2005; Sawaguchi, Franco,  
Kadhim, Mori, Ito, Taki, Sawaguchi, & Kahn, 2014).  
SIDS has been associated with prenatal neural insult in sleep areas of the developing 
brain in infants who have had prenatal alcohol exposure (Kinney, 2005). Our laboratory 
has reported that prenatal exposure to alcohol was associated with increased sleep 
fragmentation, defined as increased arousals during sleepand also suppressed SM during 
sleep (Troese, Fukumizu, Sallinen, Gilles, Wellman, Paul, & Hayes, 2008). This pattern 
of sleep disturbance is associated with the development of sleep deprivation. In a study of 
premature infants who have a significantly higher than average risk of SIDS, our 
laboratory has found that arousals and awakenings eventually decrease with increasing 
days of sleep fragmentation, as would SMs (Hayes, Akilesh, Fukumizu, Gilles, Sallinen 
et al, 2007).  Hence, SIDS risk groups such as premature births, and infants with prenatal 
exposure to alcohol were both associated with poor sleep quality, increases and eventual 
decreases in arousals and awakenings, and suppressed activation of SM. This thesis study 
is designed to examine another prenatal exposure, the synthetic opioid methadone, which 
has similarly been associated with increased SIDS rates (Hunt, 2008). The thesis study 
will investigate the characteristics of sleep quality, sleep-related arousals, and SM 
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patterning in neonates who have been prenatally exposed to the opioid methadone taken 
daily by the mother for opioid dependence.   
1.1. Neuropharmacology of Opioid Addiction 
 The next section will examine the fundamentals of opioid addiction and 
dependence to provide background for neonatal dependence in NAS.  Koob (2008) 
describes drug addiction as a disorder governed by motivation, which is modulated by the 
reward circuitry of the brain. This process begins with elevated motivation to experience 
the hedonic or rewarding influence of the drug (impulsivity) followed over time by the 
desire to avoid the anhedonia (i.e., lack of pleasure) and unpleasant consequences of 
withdrawal (compulsivity). According to Koob, common motivation-driven cyclical 
characteristics of addiction include craving, tolerance, dependence, withdrawal, and 
relapse; and these processes are mediated by the mesoaccumbens dopamine (DA) system, 
in which mesolimbic DA is projected from the ventral tegmental area (VTA) primarily to 
the nucleus accumbens (NAc), as well as the medial prefrontal cortex (mPFC), amygdala, 
and ventral pallidum. Repeated exposure to drugs eventually alters this neurocircuitry 
causing both synaptic-level and systems-level plasticity.  
Neuroadaptation is the transformation of reward to a habitual state from drug 
related activation of this system. In this thesis, it is proposed that early developmental 
changes in drug-related reward circuitry might reduce children’s reward level by setting a 
higher bar for eliciting a hedonic effect. This change results in the activation of aversive, 
or anti-reward, circuitry (Koob, 2008). Koob’s theory of the underlying mechanism of 
addiction indicates that withdrawal symptoms frequently occur as an aftermath of drug 
dependence. Among drugs with high potency for dependence, are opiates. 
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Opioid prescription medications leading to dependence and methadone 
replacement therapy is the background of mothers in the current study in which the 
developing fetus is exposed to opioids through maternal use during pregnancy. Maternal 
opioid medications, such as methadone, affect the developing fetus through placental 
transfer and membrane changes that improve opioid absorption during the last trimester. 
Fetuses exposed to opioids after thirty-four weeks gestational age are more likely to 
develop an abstinence syndrome than those born earlier (Barr, McPhie-Lalmansingh, 
Perez, & Riley, 2011). In infants, withdrawal is a similar process as that observed in 
adults.  Therefore, prenatal exposure to drugs of abuse followed by neonatal withdrawal 
may pose significant neuroadaptive consequences to the developing brain.  
Opioids are psychoactive chemical substances that can exert analgesic and 
rewarding effects by binding to opiate receptors, which are distributed widely in different 
areas of the brain. In a recent review, Waldhoer, Bartlett, and Whistler (2004) reported 
that opioid receptors are primarily located in the central (CNS) and peripheral nervous 
system (PNS) as well as in the gastrointestinal tract (GI).  
Four major types of opiate receptors have been identified: mu (MOR-OP3), delta 
(DOR-OP1), kappa (KOP-OP2), and nociception receptors (NOP-OP4), according to 
Stein, Schäfer, and Machelska (2003) as well as Fine (2004).  These authors further 
specify the locations and respective functions of these receptors. The primary locations of 
DOR-OP1 are the pontine nuclei, amygdala, olfactory bulbs, and deep cortex of the brain. 
This receptor has two subtypes – delta1 and delta2 – and is believed to be responsible for 
eliciting analgesia, antidepressant effects, convulsion effects, and physical dependence. It 
is also suspected to play a role in mu-opioid receptor-mediated respiratory depression or 
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hypoventilation. KOR-OP2 is found in the hypothalamus, periaqueductal gray, and 
claustrum of the brain, and also in the substantia gelatonisa of the spinal cord. The 
primary functions of these receptors are analgesia, anticonvulsant effects, dissociative and 
deliriant effects, diuresis, dysphoria, miosis or pupil constriction, neuroprotection, and 
sedation. Three currently identified subtypes of MOR-OP3 are mu1, mu2, and mu3. These 
receptors are located in the areas of brain such as cortex, thalamus, striosomes, 
periaqueductal gray, and rostral ventromedial medulla, in the substantial gelatinosa of 
spinal cord, in the intestinal tract, and the peripheral sensory neurons. The primary 
functions of these receptors are subtype-specific such that mu1 functions to elicit 
analgesia and physical dependence; mu2, is responsible for respiratory depression, miosis, 
euphoria, reduced GI motility, and physical dependence; and mu3 for vasodilation. The 
NOP-OP4 receptors are located in the areas of brain namely cortex, amygdala, 
hippocampus, septal nuclei, habenula, and hypothalamus, and in the spinal cord. 
These endogenous opioid systems are crucial in modulating the sensation of pain 
and pleasure (Fine, 2004). Prolonged, repeated exposure to narcotics derived from nature 
as well as synthetic opioids may compromise this system such that the body becomes 
sensitized to the effects of opioids and requires higher levels of opioids to elicit an 
adequate amount of effect. This could result in the development of opiate dependence. 
Therefore, the effect of synthetic opioids is associated with a rewarding, pain-free, or 
even pleasant experience (Fine, 2004; Stein et al., 2003; Waldhoer et al., 2004). 
1.1.1. Neonatal Outcomes of Prenatal Exposure to Opioids. Prenatal exposure to 
substances of abuse such as opioids has been associated with less optimal neonatal 
outcomes. Opiate addiction is typically polydrug abuse where multiple drugs are used. 
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The most common co-occurring substances are alcohol, tobacco, and marijuana. The 
sociodemographic population at greatest risk for opiate addiction is more likely to use 
other drugs of abuse, especially tobacco, alcohol and marijuana (Hayes, Brown, 
Hofmaster, Davare, Parker, & Raczek, 2002). Patrick et al. (2012) report that infants with 
prenatal opioid exposure show significant likelihood for respiratory diagnoses, low birth 
weight, feeding difficulties and seizures. In a recent report, Negrato and Gomes (2013) 
found that low-birth weight was likely a consequence of intrauterine insults such as 
maternal substance abuse. Low-birth weight is associated with health complications such 
as breast and testicular cancer, osteoporosis, cardiac hypertonicity, lack of alertness, and 
instability of mood in adulthood. These findings in combination with the consistent 
prevalence of low-birth weight among opiate-exposed infants are some of the examples 
of concern that make the investigation of prenatal opiate exposure-related developmental 
outcomes crucial to the health of at-risk children. 
Prenatal exposure to opiates, often in combination with cocaine, has been associated 
with early life neurodevelopmental adversities including infant mortality such as Sudden 
Infant Death Syndrome or SIDS (Burns, Conroy, & Mattick, 2010). Conradt, Sheinkopf, 
Lester, Tronick, LaGasse et al. (2013) found prenatal opioid exposure to be associated 
with the highest level of heart rates and the lowest level of respiratory sinus arrhythmia 
(RSA) which indicate suboptimal autonomic functioning.  Janssen, DiPietro, Elko, 
Williams, Milio, and Velez (2012) have studied RSA during fetal life. RSA is a variation 
in heart rate that occurs naturally during a breathing cycle such that heart rate increases 
during inhalation and slows down during exhalation. Such a pattern of heart rate is 
termed heart rate variability or HRV. In the same study, the opiate-exposed fetuses post 
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birth showed more non-optimal reflexes and stress/abstinence signs, poorer quality of 
movements and increased hypertonicity during a sustained visual task using the NICU 
Intensive Care Unit Neurobehavioral Scale (NNNS; Lester, 2004). These results indicate 
that autonomic nervous system (ANS) dysfunction is of concern in infants born with 
prenatal exposure to opiates and cocaine, and the developmental outcomes of these 
infants in early life is neurobehaviorally poorer than comparison samples. 
 1.1.2. Treatment of Opioid Addiction During Pregnancy. A current standard of 
care for treating opiate dependence during pregnancy is the narcotic treatment program 
(NTP). Clinically controlled substitutes such as buprenorphine or methadone are used to 
prevent opioid drug seeking and to promote harm reduction during pregnancy (Patrick et 
al., 2012). For this thesis, all mothers in the methadone-exposed group were enrolled in 
the NTP and maintained on methadone.  
Lugo, Satterfield, and Kern (2005) state that methadone is a lipophilic, synthetic 
opioid that is a µ-opioid receptor agonist, a weak NMDA agonist, and inhibitor of the 
production of cyclic adenosine monophosphate (cAMP) at the cellular level.  Methadone 
accumulates at tissue binding sites, and is released into plasma during redistribution. This 
contributes to a significantly longer half-life (24 hours) or duration of influence compared 
to its counterparts in addition to being cost effective, which makes it an ideal substance 
for opiate replacement therapy (Jones et al., 2010). Methadone is valued for its qualities 
to exhaust cravings for opiates for a relatively longer period of time, stop physiological 
withdrawal symptoms, and prevent the euphoric effect associated with illicit opioid abuse 
(Kreek, 2000; Ward, Drover, Hammer, Stemland, Kern et al.,2014). Methadone is also 
considered safer, as proposed by Jones, O'Grady, Malfi, and Tuten (2008), for pregnant 
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opiate-dependent women and their fetus in comparison to continued prescription 
painkiller or heroin abuse because the treatment provides them with consistency in daily 
opiate doses as opposed to irregular binge and withdrawal cycles that are characteristics 
of street narcotic abuse. Another advantage of being in treatment, as mentioned by Jones 
et al., is that the use of other substances of abuse is monitored through random drug 
screens that occur at least monthly. The pharmacological testing performed by Affiliated 
Laboratories, Inc., of Bangor, Maine included urinary drug screens (UDS) for 
benzodiazepines, cocaine, methylphenidate, cocaine metabolites, cannabinoids, lysergic 
acid diethylamide, buprenorphine (subutex), methadone and methadone metabolites, 
oxycodone, barbiturates, cotinine, and other drugs during pregnancy and postnatally for 
the methadone-exposed group mother of the present study. Also, screening for alcohol 
was done by using breathalyzers at the time of UDS. However, it is not always possible to 
trace in-utero alcohol exposure through theUDS alone. Therefore, an exposure to alcohol 
was also ascertained through careful clinical interview with standard methods that were 
included in this thesis.  
Nanovskaya, Nekhayeva, Hankins, and Ahmed (2008) report that the placenta is 
permeable to maternal use or consumption of substances such as alcohol, tobacco, and 
opioids and that the rate of fetal exposure to opioids is the highest during the 3rd trimester 
when the placental barrier becomes highly permeable, thus, increasing the concentration 
of penetrated substances in the fetal environment. The underlying mechanism of this 
increased permeability during the 3rd trimester is purported to result from the readiness of 
the fetus to absorb as many nutrients as possible from maternal blood in order to ramp up 
the growth process in preparation for the upcoming birth.  On the other hand, the same 
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mechanism also may cause the maternal dose of methadone to permeate the placental 
barrier more readily, and this may result in the fetus becoming an additional consumer of 
the maternal dose, which may cause an earlier-than-usual experience of withdrawal in 
mothers. Therefore, Logan, Brown, and Hayes (2013) suggest a careful maternal dose 
management to be recommended to the methadone maintained mothers especially during 
the 3rd trimester of gestation by following the most practiced paradigm (i.e., split-dose as 
opposed to once-a-day dose) in order to increase methadone half-life and avoid potential 
repeated fetal withdrawal cycles that may cause severe neurobehavioral consequences 
including fetal mortality. Besides all the advantages of methadone treatment for opiate 
dependence during pregnancy, effects of prenatal exposure to methadone on the 
development of humans from fetal stage throughout the lifespan are relatively unknown. 
The following section presents some of the neurodevelopmental outcomes of prenatal 
exposure to methadone.  
1.1.3. Neurodevelopmental Consequences of Methadone Exposure. In order to 
fully comprehend the actual effect of methadone on neonates, taking into consideration 
the outcomes of both animal and human studies are equally importance because while 
animal studies ideally provide an insight into specific biobehavioral effects of methadone 
exposure, human studies present an opportunity to investigate those isolated effects in 
association with environmental factors to broaden our understanding of the implication of 
prenatal methadone exposure. Therefore, this thesis study attempted to look into potential 
neurodevelopmental impact of methadone exposure by examining the sleep state 
organization of the exposed neonates. 
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Due to the complexity of human substance exposure in-utero resulting from a 
highly frequent trend of poly-drug abuse among opiate-addicted pregnant women, it is 
not easy to replicate an animal model of methadone exposure, and the results may face 
translational controversies. However, carefully designed studies such as the one by 
Hutchings, Zmitrovich, Church, and Malowany (1992) using mouse pups showed dose-
dependent neurobehavioral consequences of methadone exposure in those mouse- pups at 
22 days of age where high dose pups demonstrated less restfulness, disrupted rhythmicity, 
and poor state regulation as shown by increased state lability indicating dose-specific 
neurodevelopmental abnormalities in comparison to low-dose methadone and non-
methadone pups.  
A classic study by Guo, Enters, McDowell, and Robinson (1990) primarily 
investigated the effect of methadone on the neurotransmitters cholinergic, noradrenergic, 
dopaminergic, and serotonergic neurons, which are crucial for optimal 
psychophysiological regulation in vertebrates. An osmotic minipump was used to 
administer maternal methadone. The rats were impregnated naturally by placing male and 
female rats together in the same cages. On the 8th day of gestation, two groups of 
pregnant rats were subcutaneously administered either methadone or sterile water. The 
methadone-exposed pups were postnatally injected with naloxone in order to confirm 
methadone dependence. Then 4-day old pups were sacrificed and analyzed for the 
neurotransmitters of interest. Results indicated sex-related differences in the brain region-
specific neurotransmitter content. The most important finding of this study was the 
similar reduction of striatal acetylcholine content in both male and female pups 
suggesting that prenatal methadone exposure may impair the stress regulatory system in 
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infants of both genders equally. These researchers further demonstrated the effect of 
prenatal methadone exposure on central cholingergic neuronal activity, delays in the 
development and expression of striatal cholinergic neurons, and similar effects also on 
the dopamine, norepinephrine, and serotonin systems.   
Robinson and Kolb (1997) expanded their approach to examine the impact of 
perinatal exposure to methadone on neurotransmitters more closely by using ratio of 
neurotransmitters to their corresponding metabolites during both perinatal and postnatal 
exposure to methadone. Pregnant rats were implanted with osmotic minipumps 
containing either methadone hydrochloride (initial dose, 9 mg/kg/day) or sterile water on 
day 7 of gestation. Their offspring were cross-fostered so that they were exposed to 
methadone prenatally and/or postnatally. Then those pups were analyzed for dopamine 
(DA), norepinephrine (NE), serotonin (5-HT), and their metabolites in relation to their 
metabolites (i.e., 3,4-dihydroxyphenylacetic acid (DOPAC) for DA; 3-methoxy-4-
hydroxyphenylglycol (MOPEG) for NE; and 5-hydroxyindoleacetic acid (5-HIAA) for 5-
HT) on day 21. The results indicated gender specific differences in the disruptions of the 
dopaminergic, noradrenergic, and serotonergic activity in a brain region. Males exposed 
to methadone postnatally showed reduction in the ratio of the DA metabolite DOPAC to 
DA in the frontal cortex, and this effect was not observed in the striatum. The ratio of 
MOPEG to NE in the hippocampus was increased significantly in males exposed to 
methadone prenatally. A slight increase in the striatal and parietal cortical 5-HT 
metabolite 5-HIAA was observed in rats exposed to methadone postnatally but there was 
no interaction between the ratios of 5-HT to its metabolite. The authors concluded that 
the effects of methadone exposure might be dependent on the developmental stage at 
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which exposure occurred and not so much on the neonatal withdrawal per se, and that 
changes in activity of these three neurotransmitter systems may contribute to the effect of 
perinatal methadone on the activity of other neurons. 
Putting their findings into perspective, Robinson (2000) consolidated a review of 
contemporary animal models of opioid exposure including methadone and reported that 
even though opiate replacements such as buprenorphine or methadone are considered 
non-teratogenic (i.e., not harmful to fetus) and preventative of repeated cycles of in utero 
withdrawals, there is consistency in the finding of disruption of cholinergic system 
development, particularly in the striatum of infant animals prenatally exposed to opioids. 
Such effect has been deemed surpassable with an increase in postnatal cholinergic 
neuronal activity, but even though acetylcholine (ACh) content and the expression of 
choline acetyltransferase protein and mRNA are reduced in the early postnatal period by 
prenatal opioid exposure in the rats, the activity of the cholinergic neurons remains 
disrupted, with a large increase in ACh turnover rate suggesting that the chances of 
overcoming cholinergic system deficit is low. One potential mechanism involved in this 
phenomenon is related to atypical changes in the expression of nerve growth factor 
(NGF), a neurotrophin known to influence the development of cholinergic neurons, 
which has been found to be reduced by opioid exposure (Wu, Hung, Shen, Chen, Chang 
et al., 2014). It is proposed that similar mechanisms are at work in methadone-exposed 
infants leading to abnormal cell growth and migration, increasing the risk for 
neurodevelopmental deficits.  
Unlike animal models, human exposure to maternal use of methadone is much 
more complicated due to the consistently documented issue of co-occurring multidrug use 
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in addition to clinical methadone. Therefore, the study of the nature of prenatal exposure 
to substances of abuse must rely on urinalysis screens that are merely a snapshot of recent 
exposure for most substances, with the exception of cannabis and opioids, which can 
persist for several weeks after ingestion (Katz & Fanciullo, 2002) Methadone dose and 
dose change throughout pregnancy is determined through the medical records but 
additional use is documented through random, monthly urinalysis. Since alcohol 
exposure related to maternal use is known as a profound teratogen (Riley, Infante, & 
Warren, 2011), determining dosage and timing of exposure is particularly difficult. State 
of the art method in this area relies on maternal self-report using well-established alcohol 
use instruments.  
Functional consequences of prenatal exposure to opioids is evaluated through 
neonatal neurological (imaging and motor testing), neurobehavioral [NICU Network 
Neurobehavioral Scales (NNNS)] and neurocognitive (EEG, and event related potential 
or ERP) assessments, and longitudinal postnatal behavioral observations to investigate 
the effect of methadone, and such methods bring along controversies regarding potential 
confounding variables. With an increase in the NAS incidence in the past decade, there is 
a concern that prenatal methadone exposure may increase NAS severity (Jones et al., 
2010) and may compromise both pre and postnatal development, the latter primarily 
related to CNS consequences of prolonged withdrawal, and iatrogenic effects of 
replacement opioid medications.   
Fetal neurobehavior can be viewed as an early marker of the developing nervous 
system, and any in utero insult such as opioid exposure to this system may represent a 
threat to the neural development of the fetus (Nijhuis, 2003). Even though opiate 
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replacement therapy is a safer substitute for narcotic addiction, controversies about 
whether they are safe for fetal neurodevelopment continue. Therefore in an attempt to 
investigate the nature of impact buprenorphine or methadone may have on fetal 
neurobehavior, Janssen et al. (2011) recorded fetal heart rate (FHR) and fetal movement 
of 17 opioid-dependent pregnant women maintained on replacement therapy with either 
buprenorphine or methadone. This demographically similar sample was drawn from the 
Johns Hopkins Bayview Medical Center-based multidisciplinary treatment care facility 
called the Center for Addiction and Pregnancy. Data were recorded at different time 
points (i.e., 24, 28, 32, and 36 weeks) of gestation by using ultrasound for heart rate and 
actigraphy for movement. The results showed that acceleration of fetal heart rate (a 
measure to assess HR variability) during 24 and 28 weeks of gestation was significantly 
greater for fetuses in the buprenorphine group with no acceleration at all for the 
methadone-exposed group during the recording period. Additionally, the methadone-
exposed group showed significantly suppressed fetal movement in comparison to the 
buprenorphine group suggesting that methadone may have adverse neurobehavioral 
consequences in growing fetuses.  
In another study, Coyle, Salisbury, Lester, Jones, Lin, Graf‐Rohrmeister, and 
Fischer (2012) assessed the effect of methadone versus buprenorphine exposure on 
neonatal neurobehavior on 39 full-term infants at 3, 5, 7, 10, 14-15 and 28-30 postpartum 
days by using the Neonatal Intensive Care Unit (NICU) Network Neurobehavioral Scale 
(NNNS), a standard measure of infant neurobehavioral development. The results revealed 
in favor of buprenorphine with buprenorphine-exposed infants showing significantly 
fewer stress-abstinence signs, less hypertonia, better self-regulation, less excitability, less 
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over-arousal, and less handling need to maintain a quiet alert state in comparison to 
prenatally methadone-exposed infants (Coyle et al., 2012). Additionally, the infants who 
began NAS treatment at an older age demonstrated significantly higher self-regulation 
scores, and the least amount of average excitability and hypertonia. The results suggest 
that methadone may be less optimal for neonatal neurobehavioral development.  
In the post-neonatal period, prenatal opiate exposure seems to pose a threat to 
neuronal growth as demonstrated by Hu, Sheng, Lokensgard, and Peterson (2002), who 
report that prenatal opiate exposure is associated with increased programmed cell death 
(i.e., apoptosis) in human microglia and neurons. Neuronal apoptosis is known to be 
important for the learning process and it functions by allowing for unused neurons to die 
so that active neurons get proper environment to migrate to specific locations according 
to the type of learning that has occurred. However, excessive increase of neuronal 
apoptosis could indicate deficits in the brain white matter that may interfere with 
appropriate learning processes, resulting in cognitive and behavioral dysfunctions. 
Expanding this finding, Walhovd, Watts, Amlien, Woodward, and Woodward (2012) 
examined the early cerebral connective tract development of infants born to methadone-
maintained mothers and comparison infants by using diffuser tensor imaging with an 
assumption that the methadone-exposed infants (n=15) show signs of lower neural tract 
maturation than comparison infants (n=7). The outcome variable was determined based 
on the mean diffusivity where higher diffusivity was marked as a sign of less maturation 
and myelination. All infants were scanned within 13 to 44 days post-birth by using a 
General Electric Signa HDx 3T MR scanner, and all scanned sets were checked for 
motion artifacts (i.e., EEG data resulted from unwanted movements during scanning), and 
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the researchers analyzed the voxel-based statistical analysis of the mean diffusivity by 
using the tract-based spatial statistics and permutation based statistics (Walhovd et al., 
2012). Diffusion tensor MRI (DT-MRI) is a non-invasive method to map the 
characteristics of soft tissue in which the MRI or magnetic resonance imaging signal to 
the random molecular motion of water molecules (diffusion) is sensitized by adding 
‘diffusion encoding gradients’ to a standard MR pulse sequence (Jones & Leemans, 
2011). The corpus callosum as well as eight major white matter areas was defined as 
areas of interest, and inferior longitudinal fasciculus and superior longitudinal fasciculus 
were selected as tracts of interest for analyzing the outcome difference. In order to match 
the hypothesis of this study, higher level of diffusivity was expected in infants exposed to 
methadone because high diffusivity has been associated with a sharp decrease in the brain 
maturation as well as demyelination or decrease in myelination in both human and animal 
studies. Supporting their hypothesis, the results of this study demonstrated that the 
methadone-exposed infants tended to have higher diffusivity of the brain neural tracts 
than the comparison group. These results were similar to many other human and animal 
studies indicating delay or deficit in brain maturational process as a result of prenatal 
insult, particularly opiate exposure as discussed in the article. The significance of this 
study relies on identifying early markers of neural alterations that may be predictive of 
cognitive and behavioral problems observed in existing studies pertaining to prenatal 
opioid exposure (Walhoved et al., 2012). 
Children with prenatal exposure to substances also tend to have difficulties with 
attention in the later years. To investigate early detection of attention problems in 
methadone-exposed infants, a study by Paul, Logan, Krishnan, Heller, Morrison et al., 
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(2014) from our lab used a subset of a sample from an ongoing longitudinal study to 
assess infants’ habituation to auditory stimuli within 4-15, 16-32, and 33-120 days of 
postnatal age. Habituation to novel stimuli is one of the markers for cognitive 
development as it indicates an infant’s efficiency for learning new information, and is 
measured by using the auditory oddball paradigm [a method used in electrocephalogram 
(EEG) that involves the presentation of frequent auditory stimuli with a randomly 
distributed novel high-pitched auditory stimulus presented occasionally throughout the 
testing period to examine variability in the brain waveforms in response to frequent and 
random stimuli] with primary focus on the amplitude and latency of peak-2 (P2) in 
response to novel stimuli. Results revealed that there were no group differences in the P2 
amplitude in the older groups as opposed to younger groups, indicating that postnatal 
environmental buffers may moderate possible adverse consequences of methadone in the 
long run, and the group difference observed during the youngest age range could have 
resulted from the neonatal abstinence syndrome (NAS).  
Another major pediatric health concern associated with prenatal exposure to 
methadone is impairment of visual development. Hamilton, McGlone, MacKinnon, 
Russell, Bradnam, and Mactier (2010) reported case studies of 20 of their pediatric 
patients who were exposed to methadone in utero and referred to them for visual 
anomaly. The authors used the measure of ophthalmic and orthoptic examination and 
visual electrophysiology as seemed appropriate on an individual basis. Additionally, the 
children’s case history and maternal urine toxicology were obtained for cross analysis. 
The results revealed ophthalmic abnormalities including reduction in acuity (95%), 
nystagmus (70%), delayed visual maturation (50%), strabismus (30%), refractive errors 
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(30%), and cerebral visual impairment (25%) (Hamilton et al., 2010). Of the 20 patients, 
60% had abnormal visual electrophysiology and one-fourth of the children showed 
neurodevelopmental abnormalities associated with the visual anomaly. Most importantly, 
79% of the nystagmus cases were treated for neonatal abstinence syndrome (NAS). These 
results indicate that infants with in utero exposure to methadone are at high risk for visual 
abnormalities, and NAS-treated babies are potential targets for nystagmus.  
McGlone, Hamilton, McCulloch, Boulton, Bradnam, Weaver, and Mactier (2013) 
expanded on the visual development of methadone-exposed infants in their study by 
using flash visual evoked potentials (VEPs), an EEG method that elicits brain waveforms 
upon the presence of flashed visual stimuli. The researchers recorded flash VEPs from 
infants within 3 days of birth from 100 infants prenatally exposed to methadone, and 50 
demographically matched comparison infants. The classification of VEP morphology 
consisted of mature, typical, or immature, which were categorized based on the 
amplitudes and implicit times of the major waveform components. Maternal history, 
maternal and infant urine, and meconium toxicology were used to determine drug 
exposure. The results revealed that maternal methadone-exposed infants were more likely 
to form immature waveform and the peaks of such waveforms were smaller in overall 
amplitude. More importantly, this effect persisted even after controlling for birth weight, 
cigarette smoking, and excess in utero alcohol exposure indicating that methadone 
exposure may affect visual anomaly in children and may need earliest possible attention 
to their visual health. All these short- and long-term postnatal outcomes aside, the biggest 
concern considering prenatal methadone exposure is NAS, which is experienced by many 
methadone-exposed neonates. 
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1.1.4. Neonatal Abstinence Syndrome (NAS). One persistent consequence of 
prenatal methadone exposure is NAS, which surfaces within 24-72 hours post birth 
(Finnegan et al., 1991).  NAS is a constellation of stress abstinence symptoms resulting 
from a physiological dependence to maternal use of opiates. In the clinical protocol 
described in a report to The Committee on Drugs and The Committee on the Fetus and 
Newborn by Hudak, Tan, Frattarelli, Galinkin, Green et al. (2012), NAS is characterized 
to have symptoms of tremors, irritability, sleeping problems, high-pitched crying, 
hypertonicity, poor feeding, stuffy nose, sneezing, yawning, gastro-intestinal 
dysregulation, dehydration, sweating and seizures, which together are indicators of CNS 
immaturity. NAS also poses a risk of neuromaturational deficits as manifested in the form 
of seizures, poor weight gain, dehydration and general dysregulation because of its long 
course of three to seven weeks with residual symptoms for six months or longer (Hayes 
& Brown, 2012). About 50% to 70% of these infants need pharmacological intervention  
(i.e., clonidine and/or phenobarbital) based on the severity of symptoms determined by 
the Finnegan Neonatal Abstinence Severity Index (Janssen et al., 2013). However, 
comparatively milder abstinence syndromes not requiring replacement medications have 
been reported with prenatal exposure to cocaine, nicotine, sedatives, barbiturates, SSRIs, 
etc. during pregnancy (reviewed in Janssen et al., 2012). 
Methadone-exposed infants tend to show variability in the profile of NAS - some 
exposed neonates go home in 5 days whereas many stay for longer than 3 weeks (Jones et 
al., 2010). In the clinical research, therefore, the length of hospital stay (LOS) is used as a 
benchmark to assess the severity of NAS (Patrick et al., 2012). A few known causes of 
such variability appear to be maternal methadone dose and gestational exposure to 
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benzodiazepines (Pritham, Paul, & Hayes, 2012); higher overall drug dose before 
delivery and gestational age (i.e., shorter gestation = shorter LOS) (Liu, Jones, Murray, 
COOK, & Nanan, 2010); and allelic variants in the mu opioid receptor type 1 (OPRM1) 
and catechol-O-methyl-transferase (COMT) genes (Wachman et al., 2013). In the genetic 
study by Wachman et al. (2013), single nucleotide polymorphism (SNP) in the OPRM1 
and COMT genes predicted NAS severity where AA genotypic variation in both genes 
were associated with a higher severity of NAS and AG or GG genotypes served as 
protective factors. Revisiting Koob’s theory of tolerance, tolerance results from an 
enhanced physical ability to intake a substance without having withdrawal symptoms, 
thus, reinforcing the reward system of the substance user to use more, which is a risk 
factor for addiction. If that is true, then perhaps the neonates with the minor allelic 
variants of the COMT SNP might be at risk for addiction due to enhanced tolerance to 
opiates.  
Taken together, it may be speculated that deficits in the CNS and ANS 
maturational process associated with prenatal opiate and potentially comorbid substance 
exposure. One way to investigate this possibility is by assessing sleep organization during 
the neonatal period. The association of prenatal substance exposure to sleep, wake, and 
arousal deficits has been established through previous studies in our lab in which 
perinatal alcohol appeared to mediate the effect of methylxanthine on arousal regulation 
of preterm apneic neonates (Hayes et al., 2007).  
1.2. Ontogenic and Biological Bases of Sleep and Wake 
Sleep is a ubiquitous phenomenon among vertebrates. The duration and intensity of 
sleep are regulated by the interaction of homeostatic processes, in which the requirement 
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for sleep builds during waking and is relieved by sleep, and circadian rhythm. According 
to Stern, Parmalese, Akiyama, Schultz, & Wenner, (1969), this rhythm determines the 
timing of the sleep/wake cycle according to an internal signaling system such as the 
suprachiasmatic biological clock and external signals such as the light-dark cycle. 
Circadian rhythm follows a diurnal sleep-wake pattern with 24-hour periodicity and this 
periodicity is characterized by sustained wakefulness during the daylight and sustained 
nocturnal sleep. Most adults’ sleep cycles follow this pattern and the onset and offset of 
the sleep cycle is determined by an individual’s biological clock. For example, de 
Benedictis, Larson, Kemp, Barston, and Segal (2007) suggest that individuals who are 
prone to waking up early in the morning are likely to continue waking up at the same 
time every day even if slightly sleep deprived. In mammals, sleep/wake regulation is 
conducted in the basal forebrain, which is located adjacent to preoptic and supraoptic 
levels of the hypothalamus and includes cholinergic cells as well as glutamatergic and 
GABAergic neurons. Despite an ongoing debate on the optimal amount of sleep for an 
adult, a common understanding is that a healthy adult sleeps about 7-8 hours a night for 
optimal functioning during the day. However, multiple factors may play a role in the 
timing, duration, and rhythmicity of sleep. The typical nocturnal sleep cycle in adults 
consists of the oscillation of Rapid Eye Movement (REM) and Non-rapid Eye Movement 
(NREM) sleeps, which generally repeat every 90 minutes (Roehrs, Carskadon, Dement, 
& Roth, 2005). In an overview of the neurobiology of REM and NREM sleep, McCarly 
(2007) characterizes REM sleep or paradoxical sleep as the stage when low amplitude, 
high frequency EEG activity is present, muscle tone is extremely suppressed, and the 
rapid ocular saccades occur. Most neuronal activity and dreaming are believed to occur 
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during this stage. McCarly further describes NREM sleep to have specific EEG 
oscillation called spindles (waxing and waning within the 12-15Hz sigma band frequency 
range that lasts at least 0.5 seconds), delta wave (1-3Hz), and slow rhythms. In humans, 
NREM sleep stage undergoes three different stages. The first stage (N1), also called 
drowsy sleep, is characterized by oscillation of EEG activity from alpha waves having 
frequency of 8-13Hz to theta waves of 4-7Hz, some muscle activity, and the slow rolling 
of eyes with opening and closing moderately. Consciousness of the environment starts to 
deplete. This stage typically lasts for about 1-7 minutes. The second stage (N2) is 
characterized by the appearance of sleep spindles and K-complexes ranging from 12-
14Hz EEG wave frequency and lasts for 10-25 minutes. K-complexes are the largest EEG 
frequency waves that consist of a large positive peak followed by another large negative 
peak. Metcalf, Mondale, & Butler (1971) mention that these peaks do not appear in 
infants until the age of 6 months. McCarly further describes that muscular activity 
decreases even more at this stage of NREM sleep and consciousness of the environment 
disappears completely. About 45-55% of adult sleep comprises this stage. The N2 
gradually develops into the last stage (N3) of NREM sleep. This stage is called deep sleep 
or slow-wave-sleep (SWS), which is characterized by 20-50% presence of the EEG delta 
frequency waves of 0-4Hz and lasts for 20 to 40 minutes in the first cycle. In this stage, 
the sleeper does not respond to many environmental stimuli. A typical adult sleep pattern 
follows four or five cycles of N1 – N2 – N3 – N2 – REM per night. The majority (~80%) 
of the first half of the nocturnal sleep cycle comprises NREM sleep and the most of the 
second half is spent on REM sleep.  
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Unlike adults, the sleep-wake cycles of neonates and infants are much shorter, and a 
newborn tends to awake every 3-4 hours for feeding and physiological needs. This pattern 
continues until the first few months with the majority of their time (12-18 hours a day) 
spent asleep, and about two-thirds of this sleep time is spent on active or REM sleep 
(Roehrs, et al., 2005). In a clinical review of fetal and neonatal sleep and circadian 
rhythm, Mirmiran et al. (2003) propose that the origin of sleep and circadian rhythm may 
develop during the last 10 weeks of gestation, and the sleep-wake pattern during the fetal 
period is comparable to preterm infants at 30-40 post-conceptional ages. Major 
characteristics of infant sleep include Active Sleep (AS) that is equivalent to REM sleep 
in adults, Quiet Sleep (QS) similar to adult’s NREM, and indeterminate sleep (IS) that 
has the elements of both AS and QS. Mirmiran et al. (2003) report in a review that AS 
and QS could be differentiated as early as 32 weeks of gestational age even though the 
majority of sleep cycle during this time is spent on IS. Scher, Johnson, and Davis (2005) 
expanded this hypothesis through an EEG sleep study on a subset of 33 preterm infants at 
25-30 weeks post-conceptional ages by recording over 2 to 3 hours of the sleep period. 
The results produced by Polysomnography data revealed that the majority of these 
neonates showed a sleep cyclic pattern of 68 + 19 minutes per bout, and the variability 
ranged from 37-100 minutes per bout of sleep. Another noteworthy finding of this study 
included individual variability in the cycle length but not in the state cyclicity, indicating 
that onset of sleep cycle development is potentially in progress as early as 25 weeks of 
gestation and the determining factor of the quality of sleep could be individually 
different. Despite all the possible individual variability, it has been well understood that 
continuous maintenance of sleep and circadian rhythm is essential for optimal daily 
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functioning and prolonged deprivation of sleep caused by sleep disorders or some 
biological condition has been known to have a cumulative effect on the psychobiology of 
an individual. 
1.2.1. Sleep Deprivation and Consequences. Although the neurobiological 
phenomenon of sleep has been studied through research using both humans and animals, 
most of the theories of sleep biology are derived from animal studies, and the 
assumptions pertaining to sleep-related brain plasticity have been formed based on the 
deprivation model, which is measured through behavioral observation as well as 
histology (Hayes et al., 2002). The deprivation model refers to the method that assumes 
an adverse outcome when the outcome is preceded by the deprivation of stimulus. In 
sleep related brain development, for example, research primarily focuses on depriving  
subjects of certain stages of sleep (e.g., REM) by presenting external stimuli (e.g., visual, 
auditory, physical), and compares its impact on the relative brain region between 
deprived and non-deprived subjects. 
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Figure 1.1. Potential adverse psychobiological effects of sleep deprivation. 
 http://en.wikipedia.org/wiki/Sleep 
Orzeł-Gryglewska (2010) suggests that prolonged sleeplessness can result in 
impairment of perception, lack of concentration, difficulty with vision, decrease in 
reaction time,  diminished schematic thinking that is responsible for decisions-making,  
and problems with optimal emotion regulation that can manifest as deteriorated 
interpersonal responses and increased aggressiveness. Sleep deprivation was also 
associated with the presence of micro-episodes of sleep during wakefulness that lead to 
lower efficiency of task performance and increased number of performance errors, as 
well as poor memorizing. These findings indicate that sleep deprivation may alter brain 
circuitry involving cognitive, emotional, and physiological functioning, thus placing an 
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individual with sleep deprivation at risk for adversities including a threat to personal 
well-being (e.g., automobile accidents, aggressive outburst).  
In infants, the consequences of sleep deprivation are even greater because sleep 
deprivation has been found to lead to longer-than-usual duration of sleep and decreased 
latency to REM sleep (Franco, Seret, Van Hees, Scaillet, Vermeulen et al., 2004) as well 
as decreased sleep-related arousal that is believed to be a risk factor for SIDS in infants 
(Kato, Franco, Groswasser, Scaillet, Kelmanson, Togari, & Kahn, 2003). In order to 
measure the level of sleep deprivation and the consequent arousal deficits, Franco et al. 
(2004) induced sleep deprivation and arousals on fourteen healthy infants of age 6–18 
weeks arousals in a sleep laboratory. These infants underwent polygraphic recording 
during a morning nap and an afternoon nap, and were sleep-deprived for 2 hours before 
being allowed to fall asleep. Sleep deprivation was achieved by keeping the infants 
awake for as long as possible beyond their habitual bedtimes. The results revealed that 
most sleep characteristics were similar for the normal and sleep-deprived conditions, 
except that the duration of the naps increased, whereas the latency of REM sleep and the 
density of body movements decreased. During such sleep, these infants needed more-
intense auditory stimuli for arousal compared with normal nap sleep. Additionally, sleep 
deprivation was associated with a significant increase in the frequency of obstructive 
sleep apnea episodes, especially during REM sleep, which is another risk factor for SIDS 
(Hunt & Hauck, 2006). 
In order to determine the characteristics of arousal from sleep of infants who 
eventually died of SIDS, Kato et al. (2003) monitored sixteen infants some days or weeks 
before they succumbed to SIDS. The comparison of polygraphic sleep recordings of those 
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infants with matched control infants showed that the cortical arousals in SIDS infants 
were significantly less frequent than in the control infants during both REM and non-
REM sleep (p = 0.039) in both frequency (p = 0.017) and duration (p = 0.005) measures. 
Interestingly, the infants who later died of SIDS had more frequent cortical activation 
between 9:00 P.M. and 12:00 A.M. (p = 0.038), and fewer cortical arousals between 3:00 
and 6:00 A.M. (p = 0.011). The results suggest that a deficient arousal processes in 
infants may pose a risk of SIDS in infants. 
The interaction among sleep deprivation, arousals, and SIDS appears rather complex 
though because while arousal deficit due to sleep deprivation is associated with SIDS, 
excessive arousability during sleep leads to sleep fragmentation, which is the predecessor 
of sleep deprivation (Hayes et al., 2007, 2008). Therefore based on the several 
documented associations among sleep fragmentation, deprivation, arousal deficit, and 
SIDS, it appears that while optimal amount of arousal is adaptive, hyper- or hypo-
arousability may pose a risk for adverse post-natal outcomes. Therefore it is important to 
understand the underlying mechanisms as well as the risk factors associated with these 
sleep components. 
1.2.2. Arousals and SM in Sleep. Sleep state organization is an essential marker of 
CNS and ANS maturity, common features of which, according to Hayes et al. (2007), 
include presence of arousals and SM during sleep periods in a cyclical fashion. Arousal 
criteria have been controversial due to the lack of standard operational definition that can 
be applied across studies. Vecchierini and Navalet (2002) state that the process of 
differentiating awakenings from arousal is based on the polysomnographic and behavioral 
state criteria in which awakening is believed to occur when behavioral markers such as 
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quiet or restless, open eyes, grimaces, movements, and occasional cry are present. 
Arousal in general is also defined as a physiological and psychological state of being 
awake or reactive to stimuli, which is achieved through a symphonic process of the 
reticular activating system in the brain stem, the autonomic nervous system, and the 
endocrine system stimulation leading to increases in blood pressure and heart rate that 
trigger sensory alertness, mobility, and readiness to respond (Robinson, 2000). A 
locomotive feature called SM during sleep is another measure to assess arousal quality 
during sleep in neonates. It is a sleep state dependent movement pattern predicted to 
occur periodically in a 3-5 minute window. SMs, as adapted from Prechtl (1990), is 
defined as writhing bodily movements, characterized according to amplitude and speed, 
which may be small-to-moderate or slow-to-fast, extension of the extremities 
(particularly the arms), and exhibiting an elliptical motion, making such movements 
similar in writhing quality. SMs have been believed to be a “primitive” physiological 
arousal system that offers autonomic protection in sleep during the neonatal and early 
infancy period when arousal systems are immature (Hayes et al., 1993). SMs, thus, serve 
a potential primitive and protective arousal regulatory mechanism and their effect is to 
restore airway openness and to up-regulate cardiorespiratory cycles of the medullary 
circuitry (Hayes et al., 2007). Franco, Kato, Richardson, Yang, Montemitro et al. (2010) 
state that the primary function of arousal from sleep is to allow sleep to continue in the 
face of endogenous or exogenous stimuli that normally elicit responses during 
wakefulness and also permit awakening.  Thus, arousal bears an adaptive mechanism.  
1.2.3. Substance Exposure, Sleep, and Arousal System. Abnormal sleep 
architecture including sleep apnea is common in substance dependence and withdrawal. 
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The medullary circuitry modulates autonomic tone, sleep, and arousal systems and 
develops quickly in the first few months of postnatal life. However, infants exposed to 
high levels of neurotoxic substances, including opiates, alcohol, and tobacco, often 
exhibit neural circuitry abnormalities particularly in the brainstem region (Kinney, 2005). 
As infant gestation advances, an emerging coupling mechanism of cardiac and somatic 
functioning becomes increasingly prominent and is considered a function of innervation 
of the autonomic nervous system (DiPietro, 2001). Reduced baseline heart rate and 
depressed respiration have been found in methadone-exposed infants compared to non-
exposed neonates along with significant differences in fetal cardiac-somatic coupling 
(movement-heart rate), fetal motility, and the variability of heart rate patterns in 
methadone-exposed neonates (Janssen et al., 2009), which suggest that disparities in fetal 
neurobehavior are likely to cause postnatal autonomic dysregulation. 
Endogenous opiates are known to modulate autonomic regulatory function, 
particularly respiration during sleep, and decrease arousability in adults (Kruger, 1995). 
In infants, of the many psychophysiological symptoms of neonatal withdrawal, pediatric 
sleep dysregulation appears to be a common concern, which may potentially surface due 
to abnormalities in the serotonergic system (5-HT) of the medulla oblongata (Harper, 
Kinney, Fleming, & Thach, 2000). Medulla oblongata is a brainstem region that is 
primarily responsible for modulation of cardio-respiration and arousals under homeostatic 
stress or the physiological challenges presented to maintain homeostasis similar to infants 
exposed to high levels of neurotoxic substances, including opiates, alcohol, and tobacco, 
who often exhibit circuitry abnormalities (Kinney et al., 2003; Kinney, 2005). Such a 
deficiency is believed to pose a risk for Sudden Infant Death Syndrome (SIDS) 
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particularly if infants are prenatally exposed to substances of abuse, according to Jones et 
al. (2010) who further emphasize that opiate-exposed infants are at even higher risk for 
SIDS compared to other conditions such as prematurity, alcohol and/or nicotine exposure, 
and sleep apnea.  
While there has been general consensus on the potential sleep-related developmental 
risks associated with opioids, the effect of in-utero exposure to methadone as an 
exogenous opioid on sleep-related arousal regulatory systems has not been studied yet. 
However, in adults methadone users, the most commonly reported neurobehavioral 
problem associated with methadone use is insomnia or the lack of sleep; and in pregnant 
methadone users, this problem appears to exacerbate during the 3rd trimester when 
mothers are likely to increase methadone dose due to increased permeability of the 
placenta that makes the fetus an additional consumer of the maternal dose and causes the 
mother to withdraw before 24 hours (Nanovskaya, Nekhayeva, Hankins, & Ahmed, 
2008). During this same period, fetuses are also supposed to be adapting to maternal 
sleep-wake patterns such that if the mother is suffering from insomnia, so is the fetus 
(Janssen et al., 2011), which could result in an abnormal sleep organization or sleep 
dysregulation in newborns (Symanski et al., 2002).  
Sleep dysregulation has been associated with increased sleep fragmentation, which is 
characterized by increased frequency and duration of wakefulness following sleep onset 
and decreased active sleep (Troese et al., 2008), the phenomenon previously found by 
Hayes et al. (2007) to be responsible for sleep debt or sleep deprivation, and is likely to 
decrease the frequency and duration of arousal parameters following sleep onset 
indicating a deficient arousal regulatory system. Among these outcomes, for example, 
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prematurity seems to add to the degree of risk for sleep disorders as demonstrated in a 
study by Hayes et al. (2007) on apneic pre-terms who tended to exhibit poor 
cardiorespiratory integrity especially during periods of sleep, which indicates that 
prematurity could pose a cardiorespiratory challenge during sleep and impact the sleep 
architecture of such infants. Since prematurity is one of the neonatal outcomes associated 
with opioid exposure, this finding adds to the hypothesis of this thesis that perhaps an 
exposure to exogenous opiates such as methadone could result in similar sleep-related 
neurodevelopmental abnormalities in neonates as early as from birth.  
Since the arousal system is emergent developmentally at birth, this thesis examined 
neonatal sleep architecture as early as first or second postnatal night to determine whether 
sleep and arousal features differ in neonates with prenatal opioid exposure (i.e., maternal 
methadone) compared to non-exposed, demographically similar infants. Quantitative 
deficits in arousals and wake state were hypothesized to reflect neurobehavioral 
instability in opioid-exposed infants in the pre-withdrawal period (Days 1 or 2 of life). 
Additionally, it was secondarily hypothesized that opioid-exposed infants may show more 
sleep fragmentation, e.g., shorter sleep periods as well as excessive arousability and 
irritability on day 2 than day 1 of life due to the development of opiate withdrawal. In 
addition, this study also explored the genetic factor that may contribute to the expression 
of behavioral states and SM. 
 1.2.4. Pharmacogenomics of Methadone in Sleep Wake and Arousal 
Regulation. As mentioned earlier, methadone primarily works as a µ-opioid receptor 
(OPRM1) agonist meaning that it binds to and activates the OPRM1 receptors. One of the 
many recurrently reported side effects of methadone treatment appears to be sleep 
  32 
disturbance, particularly insomnia, which calls for a close investigation of the 
pharmacogenomics of such an association. A group of Taiwanese researchers (Wang, 
Tsou, Chen, Chen, Ho et al., 2012) found an association of SNP in the OPRM1 gene to 
the change-in-libido and insomnia side effects sometimes (p<0.009). The insomnia 
finding was observed in methadone patients with the OPRM1 polymorphisms who had a 
positive urine morphine test and who did not use benzodiazepine hypnotics indicating 
that SNPs in opiate receptor genes may predict disturbed sleep regulation in adults.  
One of the adverse outcomes of prenatal exposure to opiates has been sleep 
disorder in pediatric populations and this association appears to be influenced by the 
severity of NAS (O’Brien & Jeffery, 2002). In a collaborative effort of Tufts Medical 
Center and Eastern Maine Medical Center, Wachman et al. (2013) along with our lab 
investigated the effects of single-nucleotide polymorphisms in the mu-opioid receptor 
type 1 (OPRM1) and catechol-o-methyltransferase (COMT) genes on NAS severity. Both 
of these genes have been linked to neural circuitry for addiction, including opiate and 
psychiatric risks. The dominant genetic model was used, which takes into account the 
homozygotes for the major allele (e.g., AA) in one group while the collapsed 
heterozygotes and homozygotes for the minor allele (e.g., AG/GG) in another group to 
compare group differences in outcome variables, which in this study, were length of 
hospital stay and need for NAS treatment in methadone-exposed neonates. The results 
revealed that the infants with the OPRM1 118A>G AG/GG and the COMT 158A>G 
AG/GG genotypes had shortened LOS and less need for NAS treatment compared to the 
carriers of AA genotype, suggesting that the polymorphism in the COMT gene may play a 
role in the variability of withdrawal severity in methadone-exposed neonates.  
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One explanation proposed in this study for the observed results is that the variant 
allele may cause an increase in binding affinity with beta-endorphin and a decrease in 
protein expression for the OPRM1 gene (Bond, Laforge, & Tian, 1998). Similarly, COMT 
gene transcribes COMT enzyme, one of the functions of which is to degrade or inactivate 
catecholamines such as dopamine, epinephrine, and norepinephrine at the postsynaptic 
cleft (Grossman, Emanuel, & Budarf, 1992). SNP in the COMT gene results in a valine to 
methionine mutation at position 158 (Val158Met) rs4680 (Lotta, Vidgren, Tilgmann, 
Ulmanen, Melen, et al., 1995). The Val variant catabolizes dopamine about four times 
more and faster than methionine (Lachman, Morrow, Shprintzen, Veit, Parsia, Faedda et 
al., 1996). However, the overexpression of Met variant in the brain (Zhu, Lipsky, Xu, Ali, 
Hyde, Kleinman et al., 2004) consequently decreases the enzyme activity by about 40% 
(Chen, Lipska, Halim, Matsumoto, Melhem et al., 2004) and results in an increased 
dopaminergic stimulation of the post-synaptic neuron due to a higher synaptic dopamine 
level following neurotransmitter release. So the SNP in this gene may cause reduction in 
the enzyme activity and increase the levels of catecholamines, which may result in an 
improved stress tolerance in these infants. Taken together, since NAS severity is 
associated with sleep disorders, and SNP in the COMT gene is associated with the NAS 
severity, this thesis study explored to see if there may be an association between the 
allelic variation of the COMT gene and sleep organization in neonates. Only methadone-
exposed neonates were assessed for this part of the study because the neonates in 
comparison group did not have genetic data. 
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1.3. Covariates: Periconceptional Absolute Alcohol Consumption 
Alcohol is a known teratogen that severely affects fetal growth (Goh, Hutson, 
Lum, Roukema, Gareri, Lynn et al. (2010). However, alcohol consumption during 
pregnancy is not easy to detect due to the underreporting of such cases in general self-
reported methods (Baña, Tabernero, Pérez-Muñuzuri, López-Suárez, Dosil et al., 2014; 
Hayes et al., 2002; Troese et al., 2008). Therefore, meconium bioassay is used frequently 
for assessing prenatal alcohol exposure. Bana et al. (2014) employed the techniques of 
gas chromatography/mass spectrometry and liquid chromatography/tandem mass 
spectrometry to detect drugs and markers of chronic consumption of alcohol in 
meconium to assess this phenomenon. A prospective study was performed during a period 
of 10 months among 110 infants assessing anthropometry, neuromuscular development 
and determination of toxic substances in urine and meconium. Meconium analysis was 
conducted to identify fatty acid ethyl esters (FAEEs) and ethyl glucuronide (Etg), which 
are the known meconium biomarkers for prenatal alcohol exposure (Goh et al., 2010). 
Participants were surveyed regarding the obstetric history, toxic habits, and employment 
status. The results of early detection markers analyzed in meconium (FAEE >1000 ng/g 
and/or Etg >50 ng/g meconium), showed that 34.65% of pregnant women consumed 
alcohol during pregnancy, and 17% were positive for both markers. Among the positive 
cases, 50% of those exceeding a FAEE's value of 5000 ng/g in meconium had low birth-
weight children. Notably, only 4.5% of this sample had reported occasionally drinking 
alcohol. These findings indicate that pregnancy-related drinking is highly likely to be 
under-reported and may complicate the investigation of isolated substance exposure in 
humans.  
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Extensive research involving both animal and human samples has demonstrated 
that prenatal alcohol exposure results in injury to the developing brain and adverse 
developmental consequences such as fetal alcohol syndrome (FAS), growth retardation, 
CNS anomalies, developmental impairment of cognitive processing (Green et al., 2007), 
and Due to the likelihood of under-reported incidents of alcohol use during pregnancy 
particularly in the high-risk population (Guo et al., 2010), studying ethanol exposure as a 
possible contributing co-morbid factor to opiates in population is warranted.  
In our previous study, Hayes et al. (2007) found lifetime history of alcohol 
consumption to be associated with sleep deprivation and lower sleep related arousals in 
apneic preterm neonates who were treated for apnea with caffeine or methylxanthine, a 
standard treatment protocol for pediatric sleep apnea. Additionally another of our study 
by Troese et al. (2008) also found prenatal alcohol to be associated with sleep 
fragmentation in otherwise healthy infants. Prenatal exposure to alcohol was found to 
lead to poor sleep in another study by Pesonen, Räikkönen, Matthews, Heinonen, 
Paavonen et al. (2009) that assessed 8-year-old children with sleep disorders through 
actigraphic assessments for 7 consecutive nights and found that children exposed 
prenatally to alcohol had a 2.9-fold (95% CI: 1.1 to 7.6) increased risk for having short 
sleeps and 3.6-fold (95% CI: 1.3 to 10.0) increased risk for low sleep efficiency, which 
are markers of sleep fragmentations. Importantly, these associations were not confounded 
by sex, gestational length, prenatal and perinatal complications, asthma, allergies, or 
parental socioeconomic status, and body mass index at 8 years.  
In this thesis sample (n=58), the amount of alcohol consumed per binge before 
pregnancy (i.e., AA/binge) was significantly higher (p = 0.006) for mothers in the 
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methadone group. Even though this measure was not directly reported for the current 
pregnancy, it was important to note that the pattern of historic alcohol abuse is a reliable 
predictor of under-reported alcohol use during pregnancy (Bana et al., 2014; Hayes et al., 
2002). The effects of prenatal alcohol, therefore, provide a model for evaluation of the 
impact of prenatal exposure in this study. 
 1.4. Hypotheses 
 Based on the studies and arguments presented above the following hypotheses 
were proposed and tested in this thesis study. 
1.4.1. Hypothesis 1: Behavioral States Integrity. Quantitative deficits in 
arousals and wake state are hypothesized to reflect neurobehavioral instability in opioid-
exposed infants in the pre-withdrawal period. To test whether sleep, arousal, and SM 
features differ in neonates with prenatal opioid exposure (i.e., maternal methadone 
treatment for dependence; n=31) compared to non-exposed, demographically similar 
infants (n=19), all-night, sleep studies, using videosomnography, were conducted on day 
1 or 2 of life.  
A secondary exploratory hypothesis was proposed that opioid-exposed infants 
might show more sleep fragmentation (e.g., shorter sleep periods, excessive arousal and 
cry) on day 2 than on day 1 of life due to the possible development of opiate withdrawal, 
which often begins at or around 48 hours post-birth. No differences in the behavioral state 
parameters were expected between day 1 and 2 in the outcomes of comparison infants. A 
2 (infant age) x 2 (exposure groups) analysis of variance (ANOVA) model was used to 
test the interaction. Day 1 (methadone-exposed = 18; comparison = 8) and day 2 
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(methadone-exposed = 13; comparison = 11) infants were compared for group 
differences. 
1.4.2. Hypothesis 2: Genetic Corollaries of Behavioral States and SM. 
Preliminary work from our laboratory has shown that withdrawal severity in NAS-treated 
infants differs based on single nucleotide polymorphisms (SNPSs) or allelic variants in 
the COMT (catechol-o-methyl-transferase) gene with minor allelic variants (AG or GG) 
showing shorter LOS and a fewer medication than the carriers of the major allelic variant 
(AA; Wachman et al., 2013). In this study, it was hypothesized that minor allelic 
genotypes of the SNPs in the COMT gene of opioid-exposed neonates would show better 
sleep organizational characteristics measured by sleep-wake, and SM parameters in the 
pre-withdrawal sleep study. For this hypothesis, 20 of the 35 methadone-exposed 
neonates were examined through saliva samples (Genotek OGR-250 kit with CS-1) for 
the alleles of the COMT gene and associations among sleep-related variables (SM, sleep, 
wake, and arousal parameters) in the early post-birth, pre-withdrawal period. 
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CHAPTER 2 
METHOD 
2.1. Participants 
 A subset of Caucasian (>98%) mother-infant dyads (N=58; total 116) from our 
longitudinal study (grant number: DA024806-01A2) of the University of Maine funded 
by National Institute of Health (NIH) was extracted for this thesis study. Participants 
consisted of pregnant women receiving the methadone maintenance treatment (MMT) 
program pre- or post-conception along with their neonates (N=37 mother-infant dyads; 74 
total). Mothers were recruited during the 3rd trimester of pregnancy from three sites in 
Bangor: the Acadia Hospital’s Narcotics Treatment Program (NTP), Bangor Discovery 
House, and Metro Treatment of Maine. A socio-demographically matched comparison 
group of mothers and infants (N=21 mother-infant dyads; 42 total) was also recruited. 
Both methadone-exposed and comparison groups were similar in demographic 
characteristics including alcohol and tobacco use except for the opiate use. 
2.1.1. Recruitment Sites. The majority of methadone-maintained expecting 
mothers were recruited from the Narcotics Treatment Program (NTP) at the Acadia 
Hospital, as well as the Discovery House Clinic and Metro Treatment of Maine in 
Bangor, Maine. Acadia Hospital served as the primary recruitment site for methadone-
maintained women, as it is the largest MMT in Penobscot County, serving over 600 
patients, of which 300 are female and 15% are pregnant at a given time.  
 Participants in the comparison group were recruited from the Family Practice 
Center (FPC) and Women Infant and Children (WIC) office in Bangor, Maine. The FPC 
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provides services to over 30,000 outpatients annually, and has been demonstrated in pilot 
data to be similar demographically and psychologically to the NTP sample in both 
preliminary (Heller et al., 2013; Logan et al., 2012) and historical (Hayes et al., 2002) 
data. Importantly, the FPC and WIC population have been shown in our laboratory to be 
similar to the NTP sample with respect to alcohol and tobacco use.  
2.1.2. Inclusionary and Exclusionary Criteria. Participants were pre-screened 
for initial eligibility criteria based on their age, socioeconomic status, stage of pregnancy, 
and present and past substance use. Inclusionary criteria required all prospective 
participants to be English speaking pregnant women between the ages of 18 and 40 years 
who, if enrolled into the Narcotics Treatment Program, were maintained on methadone 
(suboxone disqualified), and were diagnosed according to DSM-IV as opiate-dependent 
at the time of MMT entry. Consents to access pregnancy and birth-related medical 
records were obtained by collecting HIPAA waiver from mothers on behalf of themselves 
and their neonates. Use of tobacco products or alcohol in either sample did not disqualify, 
neither did continued illicit drug use during pregnancy or following birth in the 
methadone-exposed sample. Mothers with serious medical condition (e.g., cancer, 
diabetes) or psychopathology were excluded from the study as such conditions may 
adversely impact infant outcomes, and results may not be comparable to the rest of the 
sample. Other exclusionary criteria included preterm labor (<35 weeks gestational age), 
congenital fetal malformation, or severe obstetrical complications during delivery that 
compromised infant survival. In addition, infants must not have scored higher than 8 in 
the Finnegan scores, a diagnostic tool of neonatal abstinence syndrome (NAS) used by 
NICU nationwide, on the night of neonatal data collection. Infants were expected to be in 
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a stable environment such as the newborn nursery on the night sleep data was recorded. If 
the first night video was not usable, the data collection occurred the second night with a 
pre-established assumption that NAS symptoms start appearing within or after 48 hours 
of birth. Any data collected beyond 48 hours for the methadone-exposed group, therefore, 
was not included in this analysis. 
2.1.3. Institutional Review Board Approval. This project acquired an approval 
from the University of Maine’s Institutional Review Board (IRB) as well as Eastern 
Maine Medical Center’s IRB. The study fulfilled all requirements for Health Insurance 
Portability and Accountability Act (HIPAA) compliance.  
2.1.4. Risks and Discomforts. There were no physical risks involved with 
participating in this study. A little psychological risk was anticipated during the maternal 
interview process. Therefore, the participants were adequately informed ahead of time, 
and encouraged to let the interviewer know of any discomforts they experienced while 
answering certain items of the assessment tools. If need arose, referral to psychological 
services was available to such participants. No such incidence has happened to this date. 
2.1.5. Benefits. No direct benefits to either the mother or infant were expected as 
a result of participating in this study. Participants were made aware of the purpose of the 
study and the main objective of their participation, which was to contribute to new 
research about how the developing brain works. Upon request, summaries of individual 
assessment or results of overall findings were provided. Mothers were encouraged to 
share the results with their children’s pediatrician. 
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2.1.6. Confidentiality. All records were kept private and separate from 
identifiable information in a double-locked filing cabinet accessible only to the essential 
study personnel. All data were coded with a unique identifier to protect confidentiality. 
This study was further protected by a Certificate of Confidentiality from the National 
Institutes of Health. With this Certificate, study staff cannot be forced to give identifying 
information to any federal, state, or local civil, criminal, administrative, legislative, or 
other proceedings, even with a court subpoena. The researchers would use this certificate 
to resist any demands for information that would identify study participants, although no 
such circumstances arose.  
2.1.7. Compensation. For this part of the project, participants received a total 
sum of $175.00 compensation upon completion of the entire protocol. Of the total 
amount, $100 was awarded upon completion of the maternal interview during the 3rd 
trimester, and $75 for assessments conducted during the newborn hospital stay that 
included overnight recording of the neonatal sleep, actigraphic data collection (data not 
included in this thesis), and mother-infant saliva collection for genetic study. Saliva 
specimens were also collected during the follow-up visits in case of an inability to collect 
them during the hospital stay.  
2.1.8. Voluntary Participation. Participants were informed during the initial 
interview that their participation to the research is voluntary meaning they have the rights 
to decide whether they want to participate in the study or withdraw from it any time 
during the course of this study. This aspect of the study was emphasized repeatedly 
during any other follow-up visits in order to make sure that the participants fully 
understood their rights as research participants.  
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2.2. Materials and Measures  
Both mothers and infants were assessed using multiple IRB-approved tools for 
this thesis project.  
2.2.1. Maternal Assessments. The purpose of the maternal assessment was to 
screen for any pregnancy or pre-pregnancy drug and alcohol history, and to collect 
sociodemographic and psychological status at the time of enrollment.  
2.2.1.1. Drug and Alcohol Use Measurement. A semi-structured clinical interview was 
conducted to quantify licit and illicit drug use that occurred before or during the current 
pregnancy. Quantity-Variability-Frequency (QVF; Jacobson, Jacobson, Sokol, Martier, & 
Ager, 1993) method was used to measure all current and past substance use in which, the 
mother was asked to report use of various substances retrospectively (before conception) 
and currently (during the 3rd trimester), by detailing the quantity, frequency, and 
variability of substance use during a typical week. Pregnant participants were asked to 
describe to the interviewer how many drinks, what size drink, and what type of drink they 
would consume on a typical Friday night, and these questions were repeated for other 
days of the week. Participants were then asked the same series of questions about their 
alcohol use during pregnancy. These participants were also asked if they sometimes 
drank more than 5 glasses of beer, wine, or liquor as an assessment of binge drinking, 
followed by questions to determine the frequency of binge drinking episodes within the 
past year from the date of interview. They were also asked if they had any alcohol 
dependence treatment history and for how long. 
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In addition to the QVF, the Michigan Alcoholism Screening Test (MAST; Selzer, 
1971) was also administered, which is a structured interview consisting of 25 yes/no 
questions assessing both current and retrospective problematic alcohol consumption. 
They include questions regarding participation in Alcoholics Anonymous, arrests for 
drunk driving or drunken behavior, hospital admissions related to drinking, and loss of 
employment or significant others as a result of drinking. The MAST has a good reliability 
for detecting both lifetime history of problem drinking as well as recent past and current 
use of alcohol (Zung, 1982). A clinical score of five affirmative answers was chosen from 
the MAST as a cutoff indicative of problem drinking, as was recommended by the 
developer (Selzer, 1971). The T-ACE (Russell, 1994), a 4-question screening tool 
assessment of tolerance to alcohol also derived from the MAST, and the TWEAK 
(Russell, 1994), a 5-question screening tool assessing alcohol dependence, were also 
administered.  
Additional alcohol use variables were calculated following a completion of the 
interview. Alcohol use variables were calculated by determining the amount of alcohol 
content in the type of alcohol the participant drank. Absolute alcohol (AA) was 
determined using an algorithm based on the type of alcohol (e.g., beer, wine, and liquor 
are assigned weighted multipliers), size of the container (e.g., number of ounces per 
drink), and the number of drinks consumed during a sitting. Then AA was calculated by 
multiplying the number of drinks by the number of ounces, the product of which was then 
multiplied by the weighted multiplier for the type of drink. The AA estimate was then 
used to derive other variables related to alcohol consumption, including average AA per 
day (AA/D), AA per drinking day (AA/DD), and AA per binge (AA/binge).  
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Following the attainment of alcohol information, participants were asked if they 
had ever smoked marijuana. If so, they were asked to provide the age at which they first 
used marijuana. They were then asked to determine the age at which their period of 
heaviest use occurred as well as the frequency of use during that time period. Participants 
were asked if they had used marijuana since becoming pregnant or before they knew they 
were pregnant, and if so, asked to describe the frequency of use during pregnancy. This 
series of questions was repeated for each of the opiates (heroin, methadone, oxycodone, 
hydrocodone, codeine), cocaine and crack cocaine, barbiturates, sedatives and 
tranquilizers (e.g., Valium, Xanax), amphetamines (including prescription 
psychostimulants), methamphetamines, antidepressants, hallucinogens, and inhalants. 
Participants were also asked at what age they began smoking, the number of cigarettes 
per day currently smoked, the number of cigarettes per day they smoked at the beginning 
of their pregnancy, and whether or not they had ever tried to quit. Copies of these tools 
are attached in Appendix A. 
2.2.1.2. Hollingshead Four-Factor Index of Social Status. Hollingshead 4-factor 
Index of Social Status (Hollingshead, 1975) is a measure of socioeconomic status that 
contains questions about general demographic information as well as data on education 
and occupation of the participant and her partner. Education level and the type of 
occupation are assigned point values (education = 1 to 7; occupation = 1 to 9). For the 
weighted scores, education values were multiplied by 3 and occupation values multiplied 
by 5; and the weighted scores were then added for the participant and her partner 
individually before averaging them. The average was not computed if only one member 
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of the family worked. For families in which neither partner worked, the score belonging 
to the individual with the most education was utilized. 
 This measure was chosen because it is considered a more accurate portrayal of 
socioeconomic status than income alone.  Scores on this scale ranged from of 8 to 66 with 
higher scores indicating better SES. The index was validated utilizing the 1970 US 
Census such that the median years of school completed by the participants were 
correlated by .83 and the occupation scores by .85. Additionally, median income earned 
correlated by .78 and .67 with the occupation scores for men and women, respectively 
(Hollingshead, 1975).  Though unpublished, over 5800 articles have cited this index.  
2.2.1.3. Peabody Picture Vocabulary Test – 3rd Editions (PPVT-III). The PPVT-
III is a measure of verbal ability, which was chosen for its relatively short duration, ease 
of administration, and validated use as a rough estimate of IQ (Dunn & Dunn, 1997). The 
test consists of seventeen sets of twelve items each. For adults, the exam begins with set 
thirteen, item number 145. Each item consists of a verb or noun to be matched with one 
of the four pictures provided on the item page. The test administrator orally provides a 
word to the participant and scores the right or wrong answer on the record form. The 
assessment takes approximately fifteen minutes to administer and is intended for 
individuals between the ages of 2 and 90+ years.  The basal rule for this test is one or 
fewer items wrong in the first age-appropriate set in order to proceed to the forward sets. 
The discontinuation of test occurs upon eight or more incorrect answers in a single set.  
This measure produces a raw score, standard score, stanine, percentile rank, normal curve 
and age equivalent score. For this study, the standard score was used as an estimate of IQ 
that can range from 40 to 160 with higher scores indicating better verbal ability.  This 
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measure has internal consistencies between .92 to .98, split-half reliability of .86 to .97, 
alternate-form reliability of .88 to .96, and test-retest reliability of .91 to .94. The 
established validity of verbal ability of PPVT-III correlation ranges between .69 to.74 
with the OWLS scales, .91 with the WISC-III VIQ, .89 with the KAIT Crystallized IQ, 
and .81 with the K-BIT Vocabulary (Dunn & Dunn, 1997). 
2.2.1.4. Depression and Anxiety Measures. For the general assessment of 
pregnancy-related depression, this study used the Beck Depression Inventory – 2nd 
Edition (BDI-II; Beck, Steer, & Brown, 1996).  This widely used twenty-one item self-
report tool assesses depressive symptoms. Participants are expected to accurately identify 
and circle the number next to a statement that best describes their emotional or cognitive 
state on each item over the past two weeks including the day of assessment. Total score 
ranges from 0 to 63 with higher scores indicating greater depressive symptoms severity.  
Even though the BDI-II does not have a cutoff score to indicate clinical depression, the 
following guidelines are often used to interpret the total scores: minimal range 0-13, mild 
depression 14-19, moderate depression 20-28, and severe depression 29-63; an internal 
consistency for psychiatric patients is .86 and for non-psychiatric patients is .81 (Smarr, 
2003). 
 Symptoms Checklist 90-Revised (SCL-90-R; Derogotis, 1983) is a screening tool 
used for assessing a global distress in the areas of obsessive-compulsive thought, 
somatization, depression, anxiety, hostility, paranoid ideation, phobic, interpersonal 
sensitivity, and psychoticism. The symptoms are divided into three global indices:  global 
severity index (GSI), positive symptom distress, and positive symptom. The 
questionnaire consists of ninety symptoms evaluated using a Likert scale (0=not at all to 
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4=extremely), and participants are asked to rate how much they have been bothered by 
each symptom over the past week including the day of assessment. The raw score derived 
from the participants’ responses is then converted to a t-score. This measure rendered an 
assessment of global psychological well being beyond the depressive symptoms assessed 
by the BDI-II. Copies of these tools are attached in Appendix B. 
2.2.2. Infant Assessments. Behavioral, medical, and demographic information 
regarding the infants was collected at various time points using the following methods. 
2.2.2.1. Infant Biomarkers. Infant biomarkers of substance exposure were 
assessed during the hospital stay. Nurses from the NICU collected meconium samples 
from the diaper in the first few days of life according to the established protocol, i.e., 
nurses collect approximately 5 gm of fecal material obtained from the first bowl 
movements of the neonate (typically one diaper is sufficient), scrape the material from the 
diaper, and store it in a specified standard label container to later send it to the Affiliated 
Laboratories, Bangor, ME for screening of cocaine, opiates, cannabinoids, amphetamines, 
and phencyclidine (PCP). This is a standard procedure for opiate-exposed infants in the 
NICU at EMMC.  
 2.2.2.2. Finnegan Neonatal Abstinence Scoring System. This scoring system for 
NAS (Kaltenbach & Finnegan, 1986) has been exclusively used as a standard 
measurement of autonomic symptoms of withdrawal during the postnatal period. A score 
was assigned every four hours by EMMC nursing staff during the infant’s hospital stay. 
The study staff later obtained the daily scores from the medical record of the neonates 
after they were discharged from the hospital. A copy of this tool is attached in Appendix 
C. 
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2.2.2.3. Videography. Infant sleep, arousal, and SM linked to emergent arousal 
regulation and wake-sleep transitions (Giganti, Hayes, Akilesh, & Salzarulo, 2002; 
Symanski, Hayes, & Akilesh, 2002) were monitored through an overnight videographic 
sleep recording of neonates during the first or second postnatal night by using a SONY 
DCR-SR82 camcorder that produced time-locked, digital, infrared videographic data of 
maximum of 13 hours per neonate. 
2.2.2.4. Behavioral States. Behavioral categories for coding neonatal sleep, wake, 
arousal, and SM were derived from conventional methods used in previous research (e.g., 
Giganti et al., 2002; Symanski et al., 2002). To insure a fine-grained analysis of 
behavioral arousal coding, types of arousal were analyzed using the following categories: 
brief arousal (10-30 seconds), full arousal (>30 seconds and < 1 minute), and awakening 
(>1 minute) which we have found to be representative of neonatal wake and sleep-sate 
arousal behaviors. In order to assess sleep state arousal, it is essential to define the time 
criteria for sleep as well. For this study, sleep was considered stable if a sleep bout lasted 
longer than a minute following an onset. Within each sleep bout, behavioral observation 
of SM bouts (if they occurred) were coded when the event lasted for greater than or equal 
to 5 seconds (>5 seconds) post onset, and a latency of >5 seconds post offset was required 
to determine inter bout interval as well as quiescence periods. Research Assistants blind 
to the infant’s group status were trained to code behavioral states based on the 
Developmental Neuroscience Laboratory’s training system beginning with familiarization 
with the behavioral state coding methods of our laboratory for neonatal state coding 
(Giganti et al., 2002; Hayes, Akilesh, Gilles, Fukumizu, Sallinen, et al., 2007; Symanski 
et al., 2002;). Inter-observer reliability of >0.7 was established by using the Kappa 
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coefficient method for each behavioral state: brief arousal, full arousal, wake, transition, 
sleep, and SM separately.  
2.2.3. Medical Record Access. Maternal medical records pertaining to current 
pregnancy and delivery, and infant medical records from birth up to 1-month of age were 
harvested after obtaining HIPAA consent from the participant during the interview. 
Medical record data obtained included the date of induction into MMT, psychiatric 
diagnoses, current and historical methadone doses, results of random UDS, date of entry 
into prenatal care, and prescription drug use during pregnancy. Labor and delivery 
measures were also obtained. Infant birth parameters such as gestational age, sex, 
delivery type, birth weight and length, head circumference as well as onset of NAS 
symptoms, pharmacological treatment for NAS, Finnegan scores, hearing screen results, 
and feeding data were collected.  
2.2.4. Saliva Samples. All DNA samples were collected using Oragene kits either 
during the hospital stay or at the post discharge follow-up clinics of the same study. 
Mothers were asked to spit in the Oragene GR-500 kit tube and the infant sample was 
collected using an OG-250 DNA collection kit with CS-1 sponges. The maternal kit 
contained a tube with marks for saliva quantity measurement and a lid with solution to 
preserve the saliva. The infant kit included five cotton swabs, a pair of scissors, and 
storage kit with solution to preserve the DNA from saliva and buccal cells. These kits 
were ideal for this study as they were designed to store the collected specimen in the 
room temperature for as long as 5 years. 
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2.3. Study Design and Procedure 
Participants were divided into exposed and non-exposed comparison groups. 
Group 1 (n=37) comprised pregnant women who had been enrolled into a methadone 
maintenance program (MMT) before or during the current pregnancy. Group 2 (n=21) 
comprised a sociodemographically similar comparison mother-infant dyad group 
recruited from the Family Practice Clinic as well as the Women, Infant, and Children 
(WIC) office in Bangor, ME during the 3rd trimester; or at the time of birth while mother 
and infant were hospitalized at the EMMC. Majority of the comparison mothers were 
using nicotine during pregnancy. Therefore, cigarette smoking has been added in the 
demographic characteristics of this sample. 
2.3.1. Participant Recruitment Protocol. Prospective pregnant women were pre-
screened for the eligibility for the study based on the maternal inclusionary and 
exclusionary criteria by graduate assistants or the PI either by phone or through a face-to-
face interaction. Prospective participants had to be Caucasian pregnant women from low-
income households with no known pregnancy complications at the time of prescreening 
and no opioids present in the urine analysis. The exposure group participants had to meet 
all these criteria in addition to being enrolled into the MMT. 
2.3.2 Maternal Interview. Once the pregnant women met eligibility criteria and 
agreed to participate in the study, a semi-structured interview was performed at our lab 
space in Bangor, ME to collect maternal self-reported information regarding any prenatal 
use of drug and alcohol. In addition, sociodemographic and physiological statuses of the 
participants during the 3rd trimester of pregnancy were also collected. Informed consents 
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for both mother and infant were obtained during this visit. Consent for HIPAA-approved 
medical record access pertaining to current pregnancy and delivery for mother, and birth-
related information for infants was obtained. Maternal information on sociodemographic 
background (Hollingshead), IQ (PPVT-III), depression (BDI-II), and anxiety (SCL-90R) 
were also collected during this visit. The collected data were scored by our graduate 
assistants in the lab at the University of Maine, and double scored by trained 
undergraduate research assistants. All original files were de-identified and stored in a 
double-locked cabinet in the PI’s office. The interview process took approximately one 
hour and 15 minutes per participant and the participants were compensated with a $100 
cash or equivalent gift card at the end of this visit. 
2.3.3. Markers of Maternal Substance Use and Infant Exposure.  Besides an 
extensive prenatal maternal interview about a possible drug and alcohol use during this 
pregnancy, infant exposure to maternal substance use was also measured through 
neonatal meconium toxicology screens (MecSTAT-7) and urine toxicology screens upon 
admission to the NICU and maternal urine toxicology screens after delivery. This 
measure was useful for detecting possibly undetected poly drug use during pregnancy. 
2.3.4. Neonatal Sleep Data (24-48 h Post-birth Pre-withdrawal Periods). 
During the interview, information pertaining to possible delivery methods and tentative 
due date was obtained from the mother. Our study team started contacting the newborn 
nursery at the EMMC at least two weeks prior to due date twice a day to ensure no 
missed opportunity of pre-withdrawal neonatal data collection. Mothers were also 
requested to alert the study team about the birth within 12 hours post-birth if it occurred 
before the due date. Cardiorespiratory monitoring was initiated immediately at birth in 
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study participants and NAS scoring was initiated upon the coding of the first Finnegan 
score >8. With a purpose to collect quality videographic data, parents were 
requested/encouraged to house their neonates in the newborn nursery on the night of 
videographic data collection. However, parental wish was equally respected, which 
resulted in some variability in the location of recording such as mother’s room, newborn 
nursery, or continuing care nursery (CCN). If the first night of data collection was not 
successful, they were collected on the second night. Hence data resulted in the recording 
time of 24-48 postnatal hours. 
The study team went to the newborn nursery around the time of evening shift 
change in order to avoid family visiting hours and to personally assure that the night 
nurse for the participant was fully informed of the study conditions. A SONY DCR-SR8 
camera was set up on a sturdy tripod next to the infant’s bassinet with the camera view 
focused to cover at least the upper half of the body, and the recordings of nocturnal sleep 
period (midnight to 0500) were collected, which formed the basis for sleep, arousal and 
SM analyses. Midnight to 5AM was deemed the most optimal time as the environment 
tended to be much quieter with significantly less interruption occurring. Nurses were 
asked to use cluster care (i.e., disturb infants only as needed and for feeding during the 
night recording period). Finnegan scores were tabulated by the attending nurse following 
the feed and were inclusive of the previous 4h-interval as was normally done. If scores 
suggested active abstinence (>8), the departmental directive required scoring every 2 h. 
The main purpose of the Finnegan score in this study was to determine that the infant’s 
status was pre-withdrawal during the recording period.  
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2.3.4.1. Videographic Data Processing. Each baby had approximately 13 hours of 
video, which was the maximum capacity of the camera memory card. The camera and 
other equipment were collected the next morning from the newborn nursery at EMMC 
and brought to our University lab to download the video in the external hard drives. If the 
first night data was spoiled, data was collected the second postnatal night using the same 
procedure as the first night. Once the download was complete, the time stamp for 
midnight was calculated using an Excel spreadsheet and the segment from midnight to 5 
AM (0000-0500) was trimmed for behavioral state analysis.  
2.3.4.2. Behavioral States Coding. Trained and group-blinded undergraduate RAs 
coded and double-coded the videos using our lab computers. Coding criteria for sleep, 
wake, arousal, and SM were adapted from our previous studies mentioned below.  
 2.3.4.2.1. Coding Protocol. The following coding criteria were derived from 
Giganti et al. (2002); Hayes et al. (2007); and Troese at el. (2008), with primary reference 
to Behavioral State Criteria stated in Tohman et al. (1985). 
 Sleep. Sleep is generally divided into active and quiet types depending on the 
behavioral and physiological characteristics. For this sample, however, it was not possible 
to separate the types of sleep due to the nature of the videographic data that was 
influenced by environmental factors in the newborn nursery. Therefore, the sleep was 
coded when an infant’s eyes were shut; motor activity was either low or sporadic with 
muscle tone remaining low. Occasional mouthing and grimacing behaviors as well as SM 
may or may not have occurred. These characteristics were expected to persist longer than 
a minute (>60 secs) to be coded as sleep in this sample. Otherwise, the sleep-like 
behavior was coded as either indeterminate or whatever state the baby was in before the 
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initiation of such a behavior. Even though an identification of respiratory variability is 
important in characterizing behavioral states, it was difficult to detect respiration in this 
sample as the babies were swaddled for the most part of the videos. Therefore, the quality 
of respiration was not included while characterizing the sleep and wake states. 
 Wake. Wakefulness is an alternate state of sleep. The process of awakening 
mostly involves - but may or may not be preceded and followed by - transition events. 
For this study, wakeful state was coded when the infant’s eyes were mostly open, 
focused, and may have been scanning the environment. This state was expected to 
include crying and fussing with high or low motor activity tracked by regular respiration. 
Sometimes the baby’s eyes were not expected to be open or just one eye would have been 
open due to the environmental factors such as lighting and position. In such a scenario, 
the coder had to take into account other behavioral characteristics that met the criteria for 
a wake state. These characteristics, if continued for longer than a minute (>1 minute) was 
considered a wake state. The event with these characteristics, if lasted for less than a 
minute, was counted as an arousal. 
 Sleep State Arousals. Arousal was coded when it occurred within sleep bouts, and 
had, in addition to partial or full eye opening, all or either of the characteristics such as 
general body movements, increased heart rate, occasional grimacing, and cry or fuss. The 
neonate was usually expected to return to sleep state after this event but sometimes was 
intervened by a nurse especially if the neonate was crying or fussing. Depending on the 
duration of the event, arousal was divided into two categories: brief arousal for which, 
these characteristics had to last from 10 to 30 seconds, and for full arousal, greater than 
30 seconds up to 60 seconds.  
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 Nurse Intervention. For our sample, nurse intervention was characterized by the 
presence of an adult hands/arms/body in the camera view for longer than or equal to 5 
seconds (>5 secs) touching the baby, which may or may not have initiated or caused a 
change of state. Nurse intervention was coded for two categories: (1) within state 
intervention: an adult hand or body appeared in the camera view for at least 5 seconds to 
medicate or adjust the baby when the baby was within a stable sleep or wake state; (2) 
state changing intervention: an adult hand or body appeared in the camera view for at 
least 5 seconds, touched the neonate, and caused a state change (e.g., sleep to wake). 
 Transition. Transition event was expected to precede or follow sleep and wake 
states, and could include any of the characteristics such as SM (sleep-to-wake transition), 
yawn, drowse, and/or grimaces. SM or grimaces that occurred during a sleep bout and did 
not lead to the baby’s awakening were not coded as transition. Transition was considered 
ended when the baby achieved a stable state (i.e., awake or sleep) according to the states 
criteria.  
 Indeterminate. A state was coded indeterminate if the neonate was showing signs 
of mixed states characterized by oscillation between sleep- or wake-like states for at least 
10 seconds without any distinctive transition to a different state occurring. For example, 
if a neonate was drowsing and/or grimacing with excessive head and body movements in 
the middle of a sleep or wake bout that looked like a transition but the neonate failed to 
transition to the next state and instead retained the preceding state, such a bout was coded 
as an indeterminate state, which is also named disorganized sleep in a study by Field, 
Diego, Hernandez-Reif, Figueiredo, Schanberg, and Kuhn (2007). 
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 Cry. Frequency and duration of cry utterances were measured. Even though cry 
behavior bears a range of characteristics (LaGasse, Neal, & Lester, 2005), only the 
vocalized cries were recorded in this study due to methodological constraints. Cry events 
were recorded with 5 seconds of forgiving period between two bouts. For example, if two 
or more cry bouts occurred with less than a 5-second-gap in between, the whole set of 
bursts was coded as one whole bout. Cry has similar physiological characteristics to 
arousals or awakenings with an exception of difference in the pitch of vocalization 
(LaGasse et al., 2005). Therefore, the cry bouts that occurred within a sleep bout that met 
the duration criteria for brief arousal, full arousal, or awakening were also added in 
calculating the frequency and duration of arousal and awakenings. 
 No baby. In overnight videographic data, one issue we faced was losing sight of 
the neonates because they might have been taken away from camera view for multiple 
reasons such as for feeding, changing, or cuddling (if the neonate was distressed). In this 
study, the primary target length of video data for each neonate was 5 hours (2400-0500h) 
but many of the videos in the current sample had sections in which the infant was taken 
away from camera view or the camera was shut off for during parts of the recording 
period. This issue was problematic in consistently calculating the average duration and 
frequency of events that occurred within the 5-hour period. Therefore, the length of each 
video clip during which the neonate was removed from the camera view for two or more 
minutes was coded as “no baby,” and the total duration of the segment with missing data 
was subtracted from total video duration of each neonate before obtaining the average 
frequency and duration measures.  
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2.3.4.3. SM Coding. After isolating the sleep bouts of neonates from midnight to 
5 AM video segments, the sleep bouts were coded by our group-blinded RAs for SM bout 
frequencies and durations using an Excel template developed in our Developmental 
Neuroscience lab. The criteria for coding SM were adopted from our previous lab works 
(e.g., Hayes & Mitchell, 1998; Hayes, Plante, Kumar, & Delivoria‐Papadopoulos, 1993; 
Hayes, Plante, Fielding, Kumar, & Delivoria‐Papadopolos, 1994) and also from Prechtl 
(2001). The characteristics included neonatal writhing gross motor movements with a 
variable sequence of arm, leg, neck, and trunk movements within a sleep bout to last 
greater than or equal to five seconds (>5) with a 5-second of forgiving time in between 
two bouts. If two such bouts occurred within less than 5 seconds, it was considered one 
whole bout. Quiescence was coded when the neonate remained immobile between offset 
of one SM bout and the onset of subsequent SM bout within a single sleep event duration 
for greater than or equal to 5 (>5) seconds with the exception of occasional twitches or 
mouth movements (e.g., Hayes et al., 1994). Additionally, inter-bout interval (IBI) was 
calculated to gauge the lapse of time between two or more bout onsets within single sleep 
event duration. The observational coding task for the RA’s involved identifying and 
recording on the coding template the onset and offset of each SM bout. The template then 
rendered the total duration and frequency of SM bouts. The template was also formatted 
to compute the frequency and duration of quiescence and IBI. The outputs were imported 
to an SPSS file and further computed for the average bout duration, frequency per sleep 
bout, and proportion to total sleep time spent on each of the variables (i.e., SM, 
Quiescence, and IBI).  
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2.3.5. Genetic Data Processing. Since neonates tend to have dry mouth, the 
inside of their cheeks were swabbed and the swab heads were then secured in the OGR-
250 kit for assaying. Mothers were asked to spit in the tube provided by the OGR-500 kit 
and the tube was securely tightened after the saliva was mixed with the storage fluid. 
These specimens were stored at room temperature before sending to Tufts Medical Center 
for DNA extraction. Once the specimen arrived Tufts Medical Center Clinical and 
Translational Research Center Core Laboratory for processing, DNA was isolated and the 
regions of interest were genotyped for the following five main SNPs: 118A>G 
(rs1799971, dbSNP database; assay C_8950074_1) within the OPRM1 gene; 3435C>T 
(rs1045642, dbSNP; assay C_7586657 _20), 2677G/T/A (rs2032582, dbSNP; assays 
C_11711720C_30 and C_11711720D_40), and 1236C>T (rs1128503, dbSNP; assay 
C_7586662 _10) within the ABCB1 gene; and 158A>G (rs4680, dbSNP; assay 
C_25746809_50) within the COMT gene, using established Taqman technology 
(Wachman et al., 2013). For this thesis study, only 158A>G (rs4680, dbSNP; assay 
C_25746809_50) within the COMT gene was analyzed using the dominant model (AA vs 
AG/GG). 
2.4. Data Analysis 
2.4.1. Calculation of Event Frequency and Duration of Behavioral States and 
SM Parameters. For the analysis of behavioral states and SM parameters, the most 
commonly used method in our lab is the calculation of frequency and duration of 
individual states, the averages of which are then analyzed for overall analysis. However, 
every neonate presents with a variable set of behavioral patterns as well as the amount of 
time spent on each behavior. In addition to these obstacles, in the videographic data of 
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this study, the neonates were not always positioned in the most desired way, and were 
removed from the camera view at times that resulted in the fragmentation of total video 
length and some missing video duration. In order to adjust for such variability in the 
duration of total time per neonatal study, the total duration of “no baby” segments were 
individually subtracted before computing the average frequency, average event duration, 
and proportion of total time spend on an event for each observed behavior per neonate.  
2.4.1.1 Average Event Duration Measure. Average event duration of each 
observed behavior was obtained by dividing the total duration of each event or state by 
the total frequency of corresponding event or state for each neonatal video. 
    Sum of Event Duration 
           = Average Duration (Sec)/event 
    Sum of Event Frequency 
 
A combined average duration of full and brief arousal was also computed as a 
composite measure of arousal in order to control for the variability in arousal parameter 
across sample due to two separate arousal measures used in this study. The composite 
average duration was computed by dividing the sum of total raw durations of brief and 
full arousals by the sum total of raw frequencies of both measures for individual 
neonates.  
Sum of BA and FA Raw Durations 
= Composite Arousal Duration  
Sum of BA and FA Raw Bout Frequency 
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2.4.1.2. Average Frequency Measure. For the frequency measure of behavioral 
states, the raw sum of an event frequency total divided by total coded hour that rendered a 
frequency of a state or an event per hour.  
Sum of Raw Event Frequency 
         = Average Frequency/Hr 
Coded Video Duration (Hour) 
 
For the average frequency of SM and arousal parameters, total sum of the raw 
frequency of SM, IBI, quiescence, BA, and FA bouts were individually divided by total 
sleep bouts per neonate which provided an ‘average frequency per sleep bout’ measure 
for SM and arousal parameters. 
        Sum of Raw Event Frequency 
         = Average Frequency/Sleep Bout 
   Sum of Total Sleep Event Frequency 
 
2.4.1.3. Proportion Measure. Proportion of total coded duration spent on an event 
was obtained for behavioral state parameters in order to measure how much of the total 
time a neonate expressed a certain behavior. To obtain this measure, the duration sum of 
sleep, awakening, nursing intervention, transitioning, and indeterminate state was divided 
by total coded video duration in seconds individually for each neonatal sleep study.  
  Sum of Event Durations (Seconds) 
          = Proportion of Event Duration  
Total Coded Video Duration (Seconds) 
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The proportion measure of brief arousal, full arousal, as well as SM parameters 
was derived by replacing the denominator of the above equation with the sum of total 
sleep duration in seconds.  
 Sum of Event Durations (Seconds) 
          = Proportion of Event Duration  
Total Coded Sleep Duration (Seconds) 
 
2.4.2. Statistical Analysis. Data was analyzed using IBM Statistical Package for 
the Social Sciences - Version 21 (IBM-SPSS-21) for Windows. Measures of maternal and 
infant demographic characteristics as well as maternal drug and alcohol use were 
analyzed for group differences in methadone and comparison by using independent 
sample t-tests for continuous variables and chi-square for categorical variables. Each 
state/behavior was categorized into average duration, frequency per hour/sleep bout, and 
proportion of total coded time/sleep time categories (e.g., average sleep bout duration, 
frequency of sleep per hour, and proportion of total sleep).  
All behavioral state and SM measures were analyzed by using multivariate full 
factorial general linear mode (GLM). The independent variables were contrasted for 
difference. Factor interactions were displayed in means for overall interaction, between-
factor interaction, as well as within-factor interactions. Main effects were computed with 
confidence interval adjusted to LSD at 5% significance level. Homogeneity of variance 
was analyzed using Levine’s test. After performing an exploratory analysis using 
Pearson’s correlations and independent sample t-tests, AA/binge was found to be 
  62 
significantly different (p = 0.006) between the two exposure groups. Therefore AA/binge 
was added in the model as a covariate.  
Hypothesis 1 was tested using the abovementioned model on behavioral state 
parameters (frequency and duration measures of sleep, wake, arousal, cry, nursing 
intervention, transition, and indeterminate state) and SM parameters (frequency and 
duration measures of SM, non-movement quiescence, and IBI). 
For Hypothesis 2, allelic variants in the COMT gene were identified and divided 
into AA and AG/GG groups according to the dominant model (e.g., Wachman et al., 
2013) and used as a two level factor in the multivariate full factorial GLM to test whether 
polymorphisms in the COMT gene would influence the expression of SM and behavioral 
states parameters. 
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CHAPTER 3 
RESULTS 
3.1. Demographic Characteristics 
Table 3.1 shows the summary of total participants used per study for this thesis. 
The sleep study included 58 mother-infant dyads, of which 37 dyads were in the 
methadone-exposed group and 21 were in the comparison group. Of the 58, a subset of 50 
(methadone-exposed=31, comparison=19) dyads comprised the sample for behavioral 
state analysis, 38 (methadone-exposed=25, comparison=13) for SM analysis, and 20 
dyads (methadone-exposed =20) for the genetic study.  
 
 The 58 dyads were further divided into infant age categories - day 1 and day 2 -
based on neonatal age at the time of sleep recording. The methadone-exposed group had 
21 neonates in the day 1 group and 16 neonates in the day 2 groups; and the comparison 
group had 9 neonates in the day 1 group and 12 neonates in the day 2 group. Altogether, 
this sample consisted of 30 one-day old neonates and 28 two-day olds. 
3.1.1. Maternal Demographics and Substance Use. All mothers were assessed 
during the 3rd trimester of pregnancy for periconceptional (i.e., before the knowledge of 
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pregnancy) use of alcohol, tobacco and other substances of abuse. Mothers also provided 
lifetime use maximum estimates of substances of use.  
 
 Table 3.2 shows group differences in maternal demographic characteristics that 
were obtained by using parametric measure (independent sample T-test) for the 
dependent variables or nonparametric measure (chi-square) for the independent variables 
as deemed appropriate. Maternal demographic characteristics such as mother’s age at 
infant birth, socioeconomic status (SES), verbal IQ (PPVT-III), prenatal depression (BDI-
II), global anxiety index (SCL-90-GSI), and number of cigarettes smoked per day during 
pregnancy were compared between groups. Results revealed that the mothers from both 
methadone-exposed and comparison groups were similar in age, SES, and PPVT-III, but 
significant group differences were observed for BDI-II [t(54) = -2.29; p = 0.026] and 
SCL-90R (GSI) [t(54) = -3.14; p = 0.003] measures. Most of the mothers across groups 
smoked cigarettes during pregnancy (mean number of cigarettes/day: comparison = 2.50; 
methadone-exposed = 9.20) but the methadone-exposed group mothers smoked 
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significantly more cigarettes per day than the comparison mothers [t(55) = -4.15; p = 
0.00].   
 
 The maternal sample was also compared for lifetime and periconceptional 
use of drugs and alcohol by applying QVF measures for assessing frequency of use/week, 
quantity of use each time and variability in the pattern of use per week. The maternal 
samples were compared for pre-pregnancy lifetime use of drug and periconceptional use 
of alcohol prior to the awareness of pregnancy and during pregnancy. The results, shown 
in Table 3.3, reveal no group differences in TWEAK, T-ACE, AA/day, and AA/DD, 
although the M group had non-significant but higher scores on these measures. The two 
groups differed significantly for the following periconceptional alcohol measures: MAST 
scores [t(54) = -2.13; p = 0.038], binge frequency per week [t(54) = -2.19;  p = 0.033], 
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and AA/binge [t(54) = -2.89; p = 0.006]. Specifically, the methadone-exposed group 
scored higher than the comparison group on these measures. Mothers were also assessed 
for lifetime use of other licit and illicit drugs. Group differences were analyzed for 
cannabinoid use, other opioids besides methadone, cocaine, sedatives, and 
antidepressants because both groups had some history of using these particular substances 
out of all that were assessed. As shown in Table 3.3, the methadone-exposed group 
showed significantly higher lifetime use of other licit and illicit drugs than the 
comparison group [marijuana: t(54) = -2.57, p = 0.014; other opiates: t(54) = -6.98, p = 
0.000; cocaine: t(54) = -3.91, p = 0.000; sedatives: t(54) = -3.89; p = 0.000; 
antidepressants: t(54) = -2.21; p = 0.032]. 
3.1.2. Infant Demographics. Table 3.4. shows neonatal health parameters such as 
length of hospital stay (LOS), gestational age (GA), birth weight (BW), and birth length 
(BL), head circumference at birth (HC), and sex for all babies as well as NAS treatment 
status for the methadone-exposed neonates only.  
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The results revealed overall higher scores for the comparison group in LOS [t(55) 
= 5.27; p = 0.00], GA [t(55) = 2.16; p = 0.04], and BW [t(55) = 2.16; p = 0.04]. LOS was 
expected to be significantly different between groups because while comparison group 
neonates go home by 2-3 days, methadone-exposed neonates must stay for 5 days 
minimum and the LOS may prolong if they experience NAS. Even though GA and BW 
were significantly different between the two groups, these variables did not have an effect 
on the neonatal behavioral state outcomes (>.05) in the analysis of covariance. 
3.2. Sleep Study 
The sleep study for this thesis included 58 mother-infant dyads. The data was 
analyzed for the frequency and duration of behavioral state categories (i.e., sleep, wake, 
cry, transition, nursing intervention, brief arousal, full arousal, and indeterminate) and 
primitive arousal categories (i.e., SM, quiescence, and inter-bout interval). Data was 
analyzed using multivariate full factorial general linear model (GLM) with exposure 
group and infant age (day 1 or 2) as independent variables to test Hypothesis 1 
concerning behavioral state and quantitative arousal measures. As shown in Table 3.3, 
AA/binge was used as a covariate in this and all GLM analyses as it differed significantly 
between exposure groups in our sample and is an established teratogen. For Hypothesis 2, 
restricted to methadone-exposed neonates, the frequency and duration parameters of 
arousal and SM were examined using GLM model with the allelic variants of the COMT 
gene (using the dominant model of allelic variants AA, AG/GG) as the independent 
variable and AA/binge as the covariate.  
3.2.1. Hypothesis 1: Behavioral States. It was expected in Hypothesis 1 that the 
methadone-exposed group neonates would show quantitative deficits in wake and arousal 
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regulation in relation to the Comparison group. Secondarily, it was hypothesized that 
infant’s age on the day of recordings (day 1 or 2) would affect neonatal behavioral 
outcomes. The direction of deficit was expected to be greater for the methadone-exposed 
group on day 1 but increased on day 2 because of the fact that neonates with methadone 
exposure could be experiencing early signs of NAS on day 2 of life and they might be 
more prone to manifesting signs of sleep fragmentations. Hypothesis 1 included 50 
(comparison = 19, methadone-exposed = 31) sleep studies for behavioral state analysis, 
one per neonate.  Table 3.5 summarizes the results. Behavioral state analysis revealed 
significant findings for arousal and cry parameters using the GLM model described 
above. A main effect of exposure group was observed for the average duration of brief 
arousal [F(1,44) = 4.601, p = 0.038], as well as duration of the composite arousal 
measures [F(1,44) = 5.262, p = 0.027]. Post hoc analyses revealed that the methadone-
exposed group showed significantly more arousability than the comparison group 
reflected in both brief and composite arousal measures (p < 0.05). A main effect of infant 
age at recording (day 1 or 2) was also found, showing increased frequency of brief 
arousals [F(1,44) = 4.920, p = 0.032], proportion of full arousals [F(1,44) = 4.301, p = 
0.044], and frequency of full arousal [F(1,44) = 4.476, p = 0.040] on day 2 of life.  
An interaction of exposure group and infant age was observed on the proportion 
of full arousal measure [F(1,44) = 4.411, p = 0.041], explained by the methadone-
exposed group showing a dramatic increase in arousability on day 2 (p<.05), not observed 
in the Comparison group and interpreted as related to withdrawal. 
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 For infant cry, an age by exposure group interaction was found for relative 
frequency [F(1,44) = 11.135, p = 0.002] and duration [F(1,44) = 9.293, p = 0.004] 
measures. These results showed that the methadone-exposed group had significantly 
higher sleep-related arousals (p < 0.05) as well as cry frequency (p < 0.05) and duration 
(p < 0.05) compared to comparison neonates. Interestingly, the direction of change in the 
duration and frequency of cry parameters was reversed in both methadone-exposed and 
comparison groups such that even though the methadone-exposed group had higher 
overall cry scores, comparison neonates were crying more on day 1 while methadone-
exposed neonates showed an accelerated level of irritability characterized by increased 
cry on day 2, which supports the secondary hypothesis of this thesis study that 
methadone-exposed neonates are probably at risk for increased sleep fragmentation on 
  70 
day 2 due to potentially compromised sleep regulatory systems in utero. Such 
hyperarousability in the methadone-exposed neonates may indicate that neonates were 
withdrawing earlier than 48 hours. All other behavioral state parameters were not 
significantly different between groups.  
Since the methadone-exposed group showed an elevated rate of arousability and 
irritability on day 2 of life, the behavioral states outcomes were further analyzed for the 
methadone-exposed neonates only in lieu of genetic corollaries in an attempt to 
understand the mechanism of primitive arousals in depth. Additionally, the effect of 
genetics on the outcomes of SM measures was also explored. 
3.2.2. Hypothesis 2: Genetic Corollaries of Arousal and SM. Neonatal SM and 
arousal parameters were explored further to test Hypothesis 2 with a prediction that 
polymorphism in the COMT gene would have a protective effect on neonates at the 
presentation of homeostatic challenges during sleep. The directionality of outcome was 
predicted to be higher for neonates with minor allelic variants (i.e., AG/GG) of the COMT 
SNP genotypes. Of the 20 exposed neonates that had genetics data, 19 had the SM data 
and 15 had the behavioral state data. Three in each of the behavioral states group and SM 
group neonates had the AA genotype; and 16 in SM group and 12 in the behavioral states 
group had the AG/GG genotypes. Analysis of full factorial multivariate GLM was 
performed with SM and arousal parameters as dependent variables and AA/binge as a 
covariate. The independent variable was the genotypes of COMT SNP gene that was 
divided into two groups: AA genotype as one group, and AG and GG genotypes collapsed 
into the second group. The genotypes in the second group are collapsed in order to 
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minimize the variability of sample distribution between groups as G allele is believed to 
occur less frequently in humans.  
The results revealed a main effect of COMT alleles on SM duration [F(1,16) = 
6.978, p = 0.018], quiescence duration [F(1,16) = 8.706, p = 0.009], and IBI duration 
[F(1,16) = 10.048, p = 0.006]. The directionality of effect was as predicted such that 
infants with the protective allelic variants (AG/GG) of the COMT SNP had significantly 
higher SM in relation to neonates with the AA genotype. In the behavioral state measures, 
a between-subject effect of COMT genotypes showed that neonates with AG/GG 
genotype had lower average composite arousal duration [F(2,12) = 9.824, p = 0.003], 
mean duration of full arousal [F(2,12) = 6.373, p = 0.013], mean cry duration [F(2,12) = 
9.383), p = 0.004]; increased sleep frequency [F(2,12) = 12.198, p = 0.001] and mean 
duration [F(2,12) = 4,784, p = 0.030] and proportion of sleep time [F(2,12) = 4.628, p = 
0.032]; increase in the frequency of awakening [F(2,12) = 4.662, p = 0.032], and decrease 
in the total awake time [F(2,12) = 4.628, p = 0.032] compared to neonates with AA 
genotype. These results are further discussed in chapter 4. 
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CHAPTER 4 
DISCUSSION 
 Early markers of sleep disturbances indicate congenital neuronal deficits in the 
arousal regulatory systems in the brainstem region. One of the functions of the brainstem 
is cardiorespiratory regulation.  Abnormality in this brain region as a consequence of 
prenatal alcohol-exposure has been associated with SIDS (Athanasia, Karavasiliadou, & 
Styliadis, 2011; Kinney, 2005). The purpose of this thesis study was to investigate 
whether prenatal exposure to methadone, and other potentially under-reported substances 
such as alcohol, could impact the neurodevelopmental integrity of a neonate that could 
result in poor sleep quality as well as a deficit in the sleep-related arousal regulatory 
systems. It was hypothesized that such deficits, if any, should manifest as early as 24 to 
48 hours of life before the withdrawal from prenatal exposure. Finally, it was proposed as 
an exploratory hypothesis that by day 2, impaired sleep may be present in the methadone-
exposed group due to the development of NAS. The role of a genetic contribution to 
sleep-wake, arousal, and SM was examined in hypothesis 2 in the methadone-exposed 
neonates only. The polymorphism in the COMT gene, which our lab has shown affects 
NAS severity, was found to also affect pre-withdrawal, neonatal sleep and sleep 
movements  
4.1. Behavioral States, SM, and Genetic Corollaries 
 In the Hypothesis 1, the methadone-exposed neonates were expected to have 
arousal deficits in relation to the non-exposed comparison group neonates. We also 
explored the effect of infant age (day 1 or 2) in these outcomes with an expectation that 
the methadone-exposed neonates would show more sleep disruption, arousals, and cry 
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bout on day 2 of life. Additionally, in the Hypothesis 2, the influence of a polymorphism 
in the COMT gene on the sleep organization of the methadone-exposed neonates was 
explored with an expectation to see that the carriers of the minor allelic variants would 
have better sleep organization and robust SM compared to the carriers of the major 
allele/This hypothesis relates to the findings by Wachman et al., (2013) that showed 
better NAS neonatal outcomes for the carriers of the G allele. 
 4.1.1. Outcome Measures, Infant Age, and Exposure Group. One of the major 
findings of this study was that the methadone-exposed group had an overall higher level 
of arousability than the comparison group,. This result suggests that the sleep deficit is 
related to sleep fragmentation (i.e., increased arousals per sleep bout), as we found with 
alcohol-exposed infants (e.g., Hayes et al., 2007), rather than the deficit in arousal that is 
seen once sleep fragmentation has led to sleep deprivation (e.g., Troese et al., 2008). This 
association was influenced by infant age such that 2-day old neonates from the 
methadone-exposed group, but not the comparison group, were more arousable and 
irritable on day 2. The behavioral states of the comparison group remained relatively 
stable on both days.  
 The hypothesis about arousal deficit due to sleep deprivation was influenced by 
the findings from our previous studies as well as from the findings that revealed that the 
neonates who succumbed to SIDS were suffering from an arousal deficiency (e.g., Kato, 
Franco, Groswasser, Scaillet, Kelmanson  et al., 2003), and that SIDS cases observed in 
alcohol exposed infants were associated with an abnormality in the brainstem serotonin 
system (Kinney et al., 2005), one of the functions of which is to regulate sleep and 
arousal. Even though arousal deficit was not observed in the present study, significant 
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signs of sleep disruption in the form of sleep fragmentation characterized by hyper-
arousability and crying during the night was seen in the methadone-exposed group but 
not in the comparison group. Sleep fragmentation is the precedence for sleep deprivation 
and arousal deficits as a function of sleep debt over time (Hayes et al., 2007). 
The level of arousals showed main effects of group in which the methadone-
exposed group was higher than the comparison group, and age, in which both groups 
were higher on day 2.  A significant interaction of group and age was also found that 
showed that the arousal measures were similar across days for the comparison group, but 
elevated for the methadone-exposed neonates on day 2. These findings do not clearly 
support a pre-withdrawal brain injury in the methadone-exposed neonates. Nonetheless, 
sleep fragmentation is clearly present in the methadone-exposed neonates by day 2 of 
life.  Hence, early in the post birth period, sleep fragmentation sets the conditions for 
sleep deprivation as the methadone-exposed infants enter the withdrawal period after day 
2. The prediction of arousal deficit in the methadone-exposed neonates at birth was not 
found. However, the findings from this study do indicate that sleep fragmentation in the 
methadone-exposed neonates is evident as a main effect of group. In early infancy, the 
excessive propensity to arouse from sleep has been associated with poor sleep quality 
(e.g., sleep disruptions and insomnia), which is known to impair daytime alertness and 
performance in adults (Franco et al., 2010). Therefore, it is predicted that excessive 
arousals due to sleep fragmentation in the methadone-exposed neonates will be 
exacerbated through the withdrawal period, and the amount of arousals would likely 
decrease to below the level of comparison neonates due to cumulative sleep debt during 
the post withdrawal period.  
  75 
 Hyperarousability and irritability that are generally observed in the NAS neonates 
during NNNS assessments (Jones et al., 2010), our observation of a comparatively higher 
rate of arousal and cry in the methadone-exposed group (p<.05) on day 2 of life may have 
also resulted from the fact that withdrawal symptomatology for exposed neonates may be 
surfacing earlier than expected by the physicians and nurses as reflected in the standard 
NICU protocol which states  that, on average, neonates take about 24 to 72 hours to 
withdraw from the pre-delivery maternal dose of methadone (Hudak et al., 2012; Logan 
et al., 2013). If this is the case, it provides evidence that neonates are suffering 
withdrawal much earlier than is evident in the Finnegan withdrawal scoring method. The 
methadone-exposed neonates may be challenged in terms of neurodevelopmental 
adaptation to the environment for basic functions besides sleep such as feeding and social 
interactions with the mother that is believed to begin immediately after birth (Fifer, 
Byrdd, Kakua, Eigsti,  Islerb et al., 2010). Fifer et al. (2010) suggest that neonates must 
adjust their physiology and behavior to the specific demands of the novel postnatal 
environment as fast as possible in order to insure survival. When neonatal sleep is 
interrupted by excessive arousals and cry, the amount of restorative sleep is consequently 
shortened leading to a compromised stress regulatory system. The hyperarousability and 
irritability during the night-time sleep period observed in the methadone-exposed 
neonates in the present study suggest that neonatal withdrawal may be evident by using 
sleep quality as an important marker of withdrawal distress. Currently, sleep is one of the 
ten markers of withdrawal, as is crying, but is a minor contributor to the assessment of 
withdrawal severity in the Finnegan score.  Earlier pharmacological intervention may be 
afforded if sleep quality is seen as a marker for developing withdrawal. In future 
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analyses, the relationship between Finnegan scores and sleep fragmentation for individual 
exposed neonates in this study will be examined. 
 4.1.2. Maternal Psychiatric Health. Mothers in the methadone-exposed group 
had significantly elevated psychiatric symptoms as indicated by the scores on depression 
and anxiety measures during the third trimester (p < .05), which is known to compromise 
the hypothalamic-pituitary-adrenal (HPA) axis of the fetus over time and potentially 
permanently affect stress regulation in their offspring (Oberlander, Warburton, Misri, 
Aghajanian, & Hertzman, 2006). Lifelong comorbidity of lower SES, addiction, 
depression, and anxiety is well documented. In this study sample, it is possible that the 
mother who suffered opiate addiction may have also suffered from elevated depression 
and anxiety throughout the pregnancy and even before pregnancy; and the impact of 
maternal psychiatric disease may have created an adverse epigenetic influence on their 
offspring (Hein, Rauh, Engel, Häberle, Dammer, Voigt et al., 2014). Fetal exposure to the 
combination of pharmacological and psychological stressors prenatally may compromise 
the child’s long-term ability to modulate stress, and may affect adaptation over time. So, 
it is possible that neonates were born exposed to excessive maternal stress through 
psychiatric disease, maternal methadone, and other illicit substances, which are less often 
seen in women in treatment, but are more common than in non-exposed comparison 
infants.  
 4.1.3. COMT SNPS Genotype and Sleep Organization. The results for genetic 
corollaries of SM and behavioral state parameters revealed that the carriers of protective 
G allele (e.g., AG/GG genotypes) had comparatively more robust SM, less arousal and 
cry, and increased sleep frequency and duration compared to neonates with the carriers of 
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risk allele (e.g., AA genotype)  indicating that the presence of G allele, previously shown 
to be responsible for shorter NAS (e.g., Wachman et al., 2013), may also serve as a 
protective factor against sleep disruptions.  
 Similar findings were observed in another study conducted by Gruber, Grizenko, 
Ben, Gauthier, de Guzman, and Joober (2006) who investigated whether underlying 
mechanism of sleep would be modulated by SNPs of the COMT gene of sleep-disordered 
children. Thirty-four children aged 7-12 years who had a clinical diagnosis of ADHD 
were assessed using actigraphic recordings. The results revealed that the children who 
were carriers of the AA genotype showed poorer sleep regulation than those who carried 
the AG/GG genotypes indicating that mutation in the COMT gene may influence 
pediatric sleep organization as was observed in our study. These findings may provide a 
partial explanation for the underlying mechanisms that may influence sleep state 
organization of the methadone-exposed neonates in the present study.   
 COMT is an enzyme that deactivates dopamine, epinephrine, and norepinephrine 
post-synaptically. Perhaps, the polymorphism in the gene producing this enzyme may 
result in a decrease in the enzyme action on these catecholamines, thus, allowing excess 
neurotransmitters to be available. Such increased availability of dopamine and 
epinephrine may provide some advantage against neonatal opiate withdrawal in neonates 
and mitigate the severity of NAS symptoms. For example, Wichers, Aguilera, Kenis, 
Krabbendam, Myin-Germeys, Jacobs et al. (2007) studied 621 women to assess an 
association between the subjective wellbeing and the polymorphism in the COMT gene. 
They found that the ability of the participants to experience reward increased with the 
number of G (Met) alleles. More interestingly, individuals with the val/val (AA) genotype 
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experienced similar amounts of subjective well-being from a ‘very pleasant event’ as 
met/met (AG/GG) individuals did from a ‘bit pleasant event’ indicating that the carriers 
of AA genotype may have a diminished sense of well-being or perhaps the AG/GG 
carriers may have an enhanced sensitivity to feel well. The findings suggest that the SNP 
in the COMT gene may create a neurobiological environment that is more suitable for 
producing positive affect as well as an increased ability to cope with stress. Future work 
on the role of COMT SNPs in NAS is ongoing in our laboratory, but the sleep health 
advantage in sleep continuity and robust sleep movements found for G carriers in my 
study expands our understanding of the impact of polymorphisms in genes of addiction in 
newborn withdrawal.  
 4.1.4. Perinatal Alcohol Effect. All significant outcomes observed in this study 
were present in covariance with the total alcohol content that the mother used per binge 
cycle before pregnancy (i.e., AA/binge). It is well known that alcohol is teratogenic (Guo 
et al., 2010). Despite all the known fetal adversities, moderate consumption of alcohol 
has recently been argued as safe during pregnancy in a large epidemiological study 
(Humphriss, Hall, May, Zuccolo, & Macleod, 2013). Nonetheless, in an investigation of 
moderate alcohol exposure on gene expression, Rosenberg, Wolff, El-Emawy, Staples, 
Perrone-Bizzozero, and Savage (2010) conducted micro-array analysis of more than 
28,000 genes in alcohol-exposed pups and found that the expression of 304 known genes 
was altered two-fold or greater in the placenta from ethanol-consuming dams compared 
with controls and about 76% of these genes were repressed in ethanol-exposed placentas. 
The observed gene expression changes involved proteins associated with central nervous 
system development, organ morphogenesis, immunological responses, endocrine 
  79 
function, ion homeostasis, and cardiovascular development, suggesting that even small 
amounts of alcohol, that is most likely to go unreported (Baña et al., 2010; Hayes et al., 
2002), may alter the expression of a large number of placental mRNAs. Methadone-
dependent mothers are suffering from addiction and typically have a history of higher 
alcohol intake than mothers who are not diagnosed with addiction. Hence, it is likely that 
the mothers with opioid addiction and history of alcohol use may exert a compromised 
epigenetic effect on their fetus by altering the ways in which their fetuses receive 
methadone.  
 4.1.5. Primary Implications. Considering the significance of a burden NAS 
poses on neonates, parents, care-providers, as well as policy-makers, a proper 
pharmacological and clinical management of this condition is crucial. This thesis study 
was conducted to examine pre-withdrawal status of sleep and arousal systems in a 
controlled study.  In the course of that effort, sleep fragmentation was found to be greater 
in methadone-exposed infants, and that this impact was due to the likely emergence of 
withdrawal on day 2. Further, amongst methadone-exposed neonate, polymorphisms in 
the COMT gene were critical in predicting the level and severity of sleep fragmentation. 
It is believed that the sleep-wake results are valuable in this regard because the sleep 
parameters are likely early neurobehavioral markers of NAS that have not been reported 
to date.  Care-providers at the pediatric care facilities as well as the parents of such 
neonates can benefit from such information by increasing their awareness of the at-risk 
neonates’ behavioral patterns during sleep and by taking extra caution while observing 
their neonates. Additionally, the duration and intensity of cry, arousals, and SM patterns 
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observed during the pre-withdrawal period can be utilized in developing a protocol for 
individualized treatment plan of the methadone-exposed neonates.  
 Since the results found in this thesis were present in covariance with pre-
pregnancy consumption of alcohol (particularly binge), an accelerated effort to detect a 
possible exposure of alcohol during pregnancy seems important. Similarly, a sustainable 
support system for psychiatric conditions such as depression and anxiety particularly 
among opioid dependent pregnant mothers could reduce the harm of methadone exposure 
to some extent by allowing the developing fetus a relatively less adverse environment. 
Finally, it would also be useful to identify additional genetic corollaries of NAS that may 
be specific to certain symptoms, such as gastrointestinal, disrupted sleep continuity, and 
other physiological as well as psychobiological symptoms to better predict the course of 
NAS illness for the individual infant.  
 In relation to the outcomes of the comparison group, it is important to note that 
the neonates in this group are considered high-risk as well because of their mothers’ low 
SES and other maternal risk factors associated with poverty such as tobacco exposure and 
maternal use of other substances such as marijuana. These risk factors influence prenatal 
as well as postnatal outcomes of these neonates. Hence, the differences and similarities 
observed in the outcomes of the comparison group are generalizable to a public health 
population where health insurance is typically public, but are less generalizable to a 
community sample inclusive of all income levels. Normative samples have been studied 
by our group, which has established benchmarks for sleep parameters including deficits 
in arousal and SM in typical neonates (Hayes et al., 1993, 1994, 1998, 2007) that serve as 
a comparison for future work.  The findings for the comparison group in the present study 
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are comparable to our work with normative samples. The sleep-wake organization 
findings with the methadone-exposed neonates are similar to other high-risk groups with 
prematurity, alcohol or other prenatal exposures, with the exception of the identification 
in the opiate sample of early opiate withdrawal on day 2.   
4.2. Methodological Strengths and Limitations  
 The biggest strength of this thesis study is that it is the first human study assessing 
arousals and SM of the methadone-exposed newborns as early as day 1 or 2 of life. 
Another strength of this study is the identification of genetic corollaries that provides new 
insight into risk and protective SNPs for sleep integrity in the early postnatal period. 
Research in clinical samples presents significant risk of confounding factors as alternative 
explanations for group findings.  In order to minimize confounding influences, the 
demographic characteristics of both methadone-exposed and non-exposed comparison 
groups were matched as closely as possible through standardization of recruitment sites 
and strategies across exposure groups, careful interview for psychiatric and substance 
abuse patterns including urinalysis for all participants and similarities in age, SES and 
mode of insurance. This resulted in the methadone-exposed group and non-exposed 
comparison group having common backgrounds with the exception of opioid dependence 
and the treatment with methadone. As a result, we were able to significantly reduce the 
confounding factors such as maternal age, education, SES, ethnicity. Nonetheless, 
important differences existed in periconceptual alcohol binge history, lifetime drug and 
alcohol history, and psychiatric health during the pregnancy, discussed in more detail 
below. Neonatal outcomes were differences in gestational age and birth weight but not in 
other growth parameters. 
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 There were significant group differences in maternal characteristics such as 
depression and anxiety as measured by BDI-II and SCL-90R, and tobacco consumption, 
which, despite my and our lab’s efforts, were not controlled in this study due to sample 
size and could not be added to model development. With regard to prenatal alcohol 
measures, several alcohol measures were significantly different between the methadone-
exposed and comparison groups. However, absolute alcohol per binge episode “before 
the knowledge of pregnancy” was used as the alcohol covariate because it showed a 
stronger association with exposure group. Therefore, the general linear model proposed 
for this study was constrained to covary alcohol exposure because of our earlier work, but 
future modeling may improve the solution, particularly for maternal depression and 
anxiety markers as described above. Another noted methodological limitation of this 
study was the inability of the examiner to control the quality of overnight neonatal video 
data, which resulted in variability in the total coded time across the sample thus 
warranting adjustment for lost data. Neonates were moved away from the camera 
frequently, and the camera was occasionally turned off accidentally at night. Additionally, 
babies were not facing the camera while sleeping in some cases, and this made it more 
difficult to determine the behavioral states of these neonates.  
 Furthermore, despite a continuous effort of the investigator to train the coders 
over several months in depth, it is also to be noted that the measures used to code the 
videos for both behavioral states and SM parameters still require additional confirmation 
through intra-class correlation. Significant computational effort was applied to automate 
and streamline data collection accuracy to reduce error but there may still be some 
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undetected inter-coder biases that may have influenced the results. For future work, these 
potential biases must be assessed. 
 In regard to the outcomes pertaining to arousals and cry during sleep, one possible 
explanation for such high arousability in the methadone-exposed group may be the fact 
that cry events within sleep that met the duration criteria for arousals were also calculated 
as arousals besides separately being calculated for cry events. Crying has similar 
underlying physiology as wake and arousals, and is thought of as a sub-state of wake 
except it involves higher-than-normal acoustic characteristics (LaGasse et al., 2005). 
Therefore, it was justified that neonatal cry occurring within a sleep state should be 
considered an arousal or a wake event depending on the duration. However, since the 
methadone-exposed group had higher cry bouts and, hence, appeared more aroused. 
Future work will further examine the duration measures of arousal in relation to cry 
features, which have been found to be disrupted in cocaine-exposed newborns (Zeskind, 
& Lester, 2001).  
 Sample distribution across groups was another limitation of this study. Even 
though the project included a total of 58 participants with sleep studies, the sample was 
not evenly distributed for the methadone-exposed (n=37) and comparison (n=21) groups. 
Our lab often has more exposed infant sleep studies as comparison infants are more 
difficult to recruit and typically healthier so have less inter-individual differences than 
exposed samples. Also, for hypothesis 2, the genetic study was small with only 20 
participants, of which only 4 were the carriers of AA genotype, and may have impacted 
the outcomes. Even though the ration of allelic distribution was similar to the distribution 
of Wachman et al. (2013), the statistical method they used was more robust due to sample 
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size. I have more genetic and sleep study participants in process that I will be able to add 
to my dataset in the future. It is also important to note that the infant age in this study was 
cross-sectional, and the differences in outcomes observed on day 1 and 2 included 
different neonates in each group. Therefore, the results may have been influenced by 
individual differences of neonates in each group. Longitudinal assessment of sleep is 
suggested for the future studies. 
 The group differences in maternal depression and anxiety were not included due 
to power constraints, and represent another limitation of this study. The association of 
depression and anxiety to sleep disruption is well documented, and maternal depression 
during pregnancy has been associated with neonatal sleep organization (Field, Diego, 
Hernandez-Reif, Figueiredo, Schanberg, & Kuhn, 2007). In their study, Field et al. (2007) 
assessed 253 women for prenatal depression and sleep disturbances during the 2nd and 
3rd trimester, and observed their newborns during sleep. The depressed women reported 
more sleep disturbances, higher anxiety, and elevated anger as well as elevated 
norepinephrine and cortisol levels during both trimesters. The newborns of the depressed 
mothers showed lowered deep sleep, more time in indeterminate (disorganized) sleep, 
were more active and cried/fussed more. These symptoms indicate disrupted sleep that 
may eventually lead to sleep deprivation. Given that these findings are similar to what 
was observed in our results, and that our methadone-exposed group participants had 
significantly higher depression and anxiety, it is possible that controlling for the 
depression and anxiety measures may influence the outcomes of this study and need to be 
included in future analysis. 
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 Gender of the neonates was another major factor that was not included in the final 
analysis of this study. In this sample, 57% of in the methadone-exposed group and 95% in 
the comparison group consisted of males. The gender difference in the comparison group 
was significantly different (p=< .005). Given the findings of this study pertains to SIDS 
risk, it is important to note that SIDS is more prevalent in males with consistent findings 
of 50% male excess (Mage & Donner, 2014). Additionally, males and females have 
different overall physiological profiles that may play a role in the expression of the 
behavioral measures assessed in this study. For example, Kraemer (2000) summarizes in 
his review why males are more at risk than female counterparts from as early as 
conception. According to his review, “fragile males” are more vulnerable than females 
even from conception, and male mortality is greater than female mortality throughout 
life. Therefore, gender difference in the exposed neonates is an important uncontrolled 
variable that may provide important results for the model of prenatal injury, SIDS risk 
and sleep development proposed in my study.  
 Lastly, it is worth noting that the genetic corollaries of behavioral states and SM 
were only available and assessed for the methadone-exposed group. The comparison 
group genetic data, if available, could have provided us with an opportunity to assess an 
interaction between the study groups and genetic variants in predicting the outcomes of 
interest, thus broadening our understanding of an underlying genetic factors affecting 
sleep organization. 
4.3. Conclusion 
 This thesis study investigated the hypothesis that prenatal methadone exposure 
may compromise neurodevelopment that may be indexed by analyzing sleep integrity and 
  86 
arousal properties during the pre-withdrawal period. Excessive increase in the 
arousability and cry as well as a deficit in the average duration of SM measure were 
observed in the methadone-exposed neonates, Additionally, the severity of such deficit 
was further enhanced by genetic factors such that the exposed neonates carrying minor G 
allele of the COMT gene, who are known to experience less severe NAS, showed 
comparatively less arousability and irritability, more robust SM, and longer duration of 
uninterrupted sleep than neonates without a G allele. Based on these observations, it is 
hypothesized that the methadone-exposed neonates show poorer sleep integrity 
characterized by sleep fragmentation, and show this difference from non-exposed, 
comparison infants on day 2 of life. Hence, methadone-exposed neonates may be 
experiencing sleep fragmentation related to opiate withdrawal earlier than 48 hours of 
life. Finnegan scores measure stress abstinence, e.g., tremors, sweating, and diarrhea, 
which generally not elevated during the sleep studies. Sleep fragmentation may represent 
an early marker of NAS and may similarly adversely affect neonatal brain development if 
not treated promptly. Therefore, to avoid such adversities, appropriate individually 
modified treatment and management of NAS is recommended to reduce the potential 
harm of prenatal methadone exposure. Disrupted sleep evidenced in this study may also 
indicate a neurodevelopmental anomaly in the arousal regulatory system modulated 
primarily by the medulla oblongata in the brainstem. The deficit in this area and an 
altered arousal regulation have been linked to SIDS, thus, indicating that the reported 
SIDS risk associated with prenatal exposure to opiates may be reflected in sleep 
fragmentation in the neonatal period that is also associated with prenatal alcohol exposure 
and the emergence of NAS. 
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APPENDIX B: Finnegan Scoring Sheet
 
 
NEONATAL ABSTINENCE SCORING SYSTEM 
Modified Finnegan Neonatal Abstinence Score Sheet1 
System  Signs and Symptoms  Score AM PM Comments 
Excessive high-pitched (or other) cry < 5 mins 2              
Continuous high-pitched (or other) cry > 5 mins 3              
Sleeps < 1 hour after feeding 3              
Sleeps < 2 hours after feeding 2              
Sleeps < 3 hours after feeding 1              
Hyperactive Moro reflex 2              
Markedly hyperactive Moro reflex 3              
Mild tremors when disturbed 1              
Moderate-severe tremors when disturbed 2              
Mild tremors when undisturbed 3              
Moderate-severe tremors when undisturbed 4              
Increased muscle tone 1              
Excoriation (chin, knees, elbow, toes, nose) 1              
Myoclonic jerks (twitching/jerking of limbs) 3              
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Generalised convulsions 5              
Sweating 1              
Hyperthermia 37.2-38.3C 1              
Hyperthermia > 38.4C 2              
Frequent yawning (> 3-4 times/ scoring interval) 1              
Mottling 1              
Nasal stuffiness 1              
Sneezing (> 3-4 times/scoring interval) 1              
Nasal flaring 2              
Respiratory rate > 60/min 1              
M
et
ab
ol
ic
/ V
as
om
ot
or
/ 
R
es
pi
ra
to
ry
 D
is
tu
rb
an
ce
s 
Respiratory rate > 60/min with retractions 2              
Excessive sucking 1              
Poor feeding (infrequent/uncoordinated suck) 2              
Regurgitation ( 2 times during/post feeding) 2              
Projectile vomiting 3              
Loose stools (curds/seedy appearance) 2              
Watery stools (water ring on nappy around 
stool) 3              
Total Score               
Date/Time               
G
as
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nt
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al
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s 
Initials of Scorer               
 
1. Finnegan LP. Neonatal abstinence syndrome: assessment and pharmacotherapy. In: Nelson N, editor. 
Current therapy in neonatal-perinatal medicine. 2 ed. Ontario: BC Decker; 1990. 
 ©  Western Australian Centre for Evidence Based Nursing & Midwifery, January 2007 (RHSET 01660A)             Page 1 of 4     All guidelines should be read in conjunction with the Disclaimer 
  113 
 
 
NEONATAL ABSTINENCE SCORING SYSTEM
The NAS score sheet lists 21 symptoms that are most frequently observed in opiate-exposed infants. Each 
symptom and its associated degree of severity are assigned a score and the total abstinence score is 
determined by totalling the score assigned to each symptom over the scoring period. 
Key points 
x The first abstinence score should be recorded approximately two hours after birth or admission 
to the nursery (baseline score). This score reflects all infant behaviour up to the first scoring 
interval time point. 
x Following the baseline score all infants should be scored at 4-hourly intervals, except when high 
scores indicate more frequent scoring. 
x The score sheet allows for 2-hourly scoring over the 24-hour period. 
x A new sheet should be started at the beginning of each day. 
x Scoring is dynamic. All signs and symptoms observed during the scoring interval are included in 
the point-total for that period.  
x If the infant’s score at any scoring interval is  8, scoring is increased to 2-hourly and continued 
for 24 hours from the last total score of 8 or higher. 
x If the 2-hourly score is  7 for 24 hours then 4-hourly scoring intervals may be resumed. 
x If pharmacotherapy is not needed the infant is scored for the first 4 days of life at 4-hourly 
intervals. 
x If pharmacotherapy is required the infant is scored at 2- or 4-hourly intervals, depending on 
whether the abstinence score is less than or greater than 8 throughout the duration of 
therapeutic period. 
x If after cessation of pharmacotherapy the score is less than 8 for the following 3 days, then 
scoring may be discontinued.  
x If after cessation of pharmacotherapy the score is consistently 8 or more, then scoring should be 
continued for the following 4 days (minimum) to ensure that the infant is not likely to develop late 
onset of withdrawal symptoms at home following discharge.  
Guide to assessment and scoring2, 3 
The neonatal abstinence syndrome scoring system was designed for term babies on four-hourly feeds and 
may therefore need modification for preterm infants. In a term infant scoring should be performed 30 minutes 
to one hour after a feed, before the baby falls asleep.  
If necessary the infant should be awakened to elicit reflexes and behaviour, but if the infant is woken to be 
scored then diminished sleep after scoring should not be recorded. A crying infant should be soothed and 
quietened before assessing muscle tone, Moro reflex and respiratory rate. 
 
High-pitched cry Score 2 if high-pitched at its peak, 3 if high-pitched throughout. Infant is scored if crying is prolonged, even if it is not high-pitched.2 
Sleep 
This is a scale of increasing severity and a term infant should receive only one 
score from the three levels of severity. A premature infant on 3 hourly feeds 
can sleep for 2½ hours at most. Scoring should thus be 1 if the baby sleeps 
less than 2 hours, 2 if less than 1 hour and 3 if the baby does not sleep 
between feeds.2 
Moro reflex The Moro or startle reflex is a normal reflex of young infants and occurs when 
a sudden loud noise causes the child to stretch out the arms and flex the legs. 
Score if the infant exhibits pronounced jitteriness (rhythmic tremors that are 
symmetrical and involuntary) of the hands during or at the end of a Moro 
reflex. Score 3 if jitteriness and clonus (repetitive involuntary jerks) of the 
hands and/or arms are present during or after the initiation of the reflex. 
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NEONATAL ABSTINENCE SCORING SYSTEM
 
Tremors This is a scale of increasing severity and an infant should only receive one 
score from the four levels of severity. Undisturbed refers to the baby being 
asleep or at rest in the cot.2 
Increased muscle tone Score if excessive or above-normal muscle tone or tension is observed - 
muscles become "stiff" or rigid and the infant shows marked resistance to 
passive movements, e.g. if the infant does not experience any head lag when 
being pulled to the sitting position; or if there is tight flexion of the infant’s arms 
and legs (unable to slightly extend these when an attempt is made to extend 
and release the supine infant’s arms and legs).4 
Excoriation Excoriations (skin abrasions resulting from constant rubbing against a surface 
that is covered with fabric such as bed linen). Score only when excoriations 
first appear, increase or appear in a new area.2 
Myoclonic jerks Score if involuntary muscular contractions which are irregular and exceedingly 
abrupt (usually involving a single group of muscles) are observed.4 
Generalised convulsions In the newborn infant generalised seizures or convulsions are often referred to 
as tonic seizures. They are most commonly seen as generalised activity 
involving tonic extensions of all limbs, but are sometimes limited to one or 
both limbs on one side. Unusual limb movements may accompany a seizure. 
In the upper limbs these often resemble "swimming" or "rowing”. In the lower 
limbs, they resemble "pedalling" or "bicycling." Other subtle signs may include 
eye staring, rapid involuntary movements of the eyes, chewing, back arching, 
and fist clenching.4 
Sweating Score if sweating is spontaneous and is not due to excessive clothing or high room temperature4 
Hyperthermia Temperature should be taken per axilla. Mild pyrexia (37.2-38.3ºC) is an early indication of heat produced by increased muscle tone and tremors. 
Yawning Score if more than 3 yawns observed within the scoring interval.2, 4 
Mottling Score if mottling (marbled appearance of pink and pale or white areas) is 
present on the infant’s chest, trunk, arms, or legs.4 
Nasal stuffiness Score if the infant sounds congested; mucous may be visible.4 
Sneezing Score if more than 3 sneezes observed within the scoring interval.2, 4 
Nasal flaring Score only if repeated dilation of the nostrils is observed without other 
evidence of lung or airways disease.4 
Respiratory rate Respirations are counted for one full minute. Score only if >60 per minute 
without other evidence of lung or airways disease.2 Score 2 if respiration 
involves drawing in of the intercostal muscles (retractions). 
Excessive sucking Score if hyperactive/disorganised sucking, increased rooting reflex, or 
attempts to suck fists or thumbs (more than that of an average hungry infant) 
are observed.3, 4 
Poor feeding Score if the infant demonstrates excessive sucking prior to feeding, yet sucks 
infrequently during a feeding taking a small amount of breast milk or formula, 
and / or demonstrates an uncoordinated sucking reflex (difficulty sucking and 
swallowing).3 Premature infants may require tube feeding and should not be 
scored for poor feeding if tube feeding is expected at their gestation.2 
Regurgitation Score if at least one episode of regurgitation is observed even if vomit is 
contained in the mouth.4 
Loose/watery stools Score if loose (curds/seedy appearance) or watery stools (water ring on nappy 
around stool) are observed. Check the nappy after the examination is 
completed if not apparent during the examination.4 
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Symptom Checklist 90-R 
 
Below is a list of problems and complaints that people sometimes have.  Please read each one carefully 
and enter the number that best describes how much you were bothered by that problem during the past 
week. 
 
Please enter only ONE. 
 
FOR THE PAST WEEK, HOW MUCH WERE YOU BOTHERED BY: 
 
 Not At All A Little Bit Moderately 
Quite A 
Bit Extremely 
1. Headaches  0 1 2 3 4 
2. Nervousness or shakiness inside  0 1 2 3 4 
3. Unwanted thoughts, words, or ideas that won't 
leave your mind 0 1 2 3 4 
4. Faintness or dizziness  0 1 2 3 4 
5. Loss of sexual interest or pleasure 0 1 2 3 4 
6. Feeling critical of others  0 1 2 3 4 
7. The idea that someone else can control your 
thoughts  0 1 2 3 4 
8. Feeling others are to blame for most of your 
troubles 0 1 2 3 4 
9. Trouble remembering things  0 1 2 3 4 
10. Worried about sloppiness or carelessness 0 1 2 3 4 
11. Feeling easily annoyed or irritated  0 1 2 3 4 
12. Pains in heart or chest  0 1 2 3 4 
13. Feeling afraid in open spaces or on the streets 0 1 2 3 4 
14. Feeling low in energy or slowed down  0 1 2 3 4 
15. Thoughts of ending your life  0 1 2 3 4 
16. Hearing words that others do not hear  0 1 2 3 4 
17. Trembling  0 1 2 3 4 
18. Feeling that most people cannot be trusted 0 1 2 3 4 
19. Poor appetite  0 1 2 3 4 
20. Crying easily  0 1 2 3 4 
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FOR THE PAST WEEK, HOW MUCH WERE YOU BOTHERED BY: 
 
 Not At All A Little Bit Moderately 
Quite A 
Bit Extremely 
21. Feeling shy or uneasy with the opposite sex 0 1 2 3 4 
22. Feeling of being trapped or caught  0 1 2 3 4 
23. Suddenly scared for no reason  0 1 2 3 4 
24. Temper outbursts that you could not control 0 1 2 3 4 
25. Feeling afraid to go out of your house alone 0 1 2 3 4 
26. Blaming yourself for things  0 1 2 3 4 
27. Pains in lower back  0 1 2 3 4 
28. Feeling blocked in getting things done 0 1 2 3 4 
29. Feeling lonely  0 1 2 3 4 
30. Feeling blue  0 1 2 3 4 
31. Worrying too much about things  0 1 2 3 4 
32. Feeling no interest in things  0 1 2 3 4 
33. Feeling fearful  0 1 2 3 4 
34. Your feelings being easily hurt  0 1 2 3 4 
35. Other people being aware of your private 
thoughts 0 1 2 3 4 
36. Feeling others do not understand you or are 
unsympathetic 0 1 2 3 4 
37. Feeling that people are unfriendly or dislike you
  0 1 2 3 4 
38. Having to do things very slowly to insure 
correctness 0 1 2 3 4 
39. Heart pounding or racing  0 1 2 3 4 
40. Nausea or upset stomach  0 1 2 3 4 
41. Feeling inferior to others  0 1 2 3 4 
42. Soreness of your muscles  0 1 2 3 4 
43. Feeling that you are watched or talked about by 
others 0 1 2 3 4 
44. Trouble falling asleep 0 1 2 3 4 
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FOR THE PAST WEEK, HOW MUCH WERE YOU BOTHERED BY: 
 
 Not At All A Little Bit Moderately 
Quite A 
Bit Extremely 
45. Having to check and double-check what you do 0 1 2 3 4 
46. Difficulty making decisions  0 1 2 3 4 
47. Feeling afraid to travel on buses, subways, or 
trains 0 1 2 3 4 
48. Trouble getting your breath  0 1 2 3 4 
49. Hot or cold spells  0 1 2 3 4 
50. Having to avoid certain things, places, or 
activities because they frighten you 0 1 2 3 4 
51. Your mind going blank  0 1 2 3 4 
52. Numbness or tingling in parts of your body  0 1 2 3 4 
53. A lump in your throat  0 1 2 3 4 
54. Feeling hopeless about the future 0 1 2 3 4 
55. Trouble concentrating  0 1 2 3 4 
56. Feeling weak in parts of your body  0 1 2 3 4 
57. Feeling tense or keyed up  0 1 2 3 4 
58. Heavy feelings in your arms or legs 0 1 2 3 4 
59. Thoughts of death or dying  0 1 2 3 4 
60. Overeating  0 1 2 3 4 
61. Feeling uneasy when people are watching or 
talking about you 0 1 2 3 4 
62. Having thoughts that are not your own  0 1 2 3 4 
63. Having urges to beat, injure, or harm someone  0 1 2 3 4 
64. Awakening in the early morning  0 1 2 3 4 
65. Having to repeat the same actions such as 
touching, counting, washing 0 1 2 3 4 
66. Sleep that is restless or disturbed  0 1 2 3 4 
67. Having urges to break or smash things  0 1 2 3 4 
68. Having ideas or beliefs that others do not share 0 1 2 3 4 
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FOR THE PAST WEEK, HOW MUCH WERE YOU BOTHERED BY: 
 
 Not At All A Little Bit Moderately 
Quite A 
Bit Extremely 
69. Feeling very self-conscious with others  0 1 2 3 4 
70. Feeling uneasy in crowds, such as shopping or at 
a movie 0 1 2 3 4 
71. Feeling everything is an effort  0 1 2 3 4 
72. Spells of terror or panic 0 1 2 3 4 
73. Feeling uncomfortable about eating or drinking 
in public 0 1 2 3 4 
74. Getting into frequent arguments 0 1 2 3 4 
75. Feeling nervous when you are left alone 0 1 2 3 4 
76. Others not giving you proper credit for your 
achievements 0 1 2 3 4 
77. Feeling lonely even when you are with people 0 1 2 3 4 
78. Feeling so restless you couldn't sit still 0 1 2 3 4 
79. Feelings of worthlessness 0 1 2 3 4 
80. Feeling that familiar things are strange or unreal 0 1 2 3 4 
81. Shouting or throwing things 0 1 2 3 4 
82. Feeling afraid you will faint in public 0 1 2 3 4 
83. Feeling that people will take advantage of you if 
you let them 0 1 2 3 4 
84. Having thoughts about sex that bother you a lot 0 1 2 3 4 
85. The idea that you should be punished for your 
sins 0 1 2 3 4 
86. Feeling pushed to get things done 0 1 2 3 4 
87. The idea that something serious is wrong with 
your body 0 1 2 3 4 
88. Never feeling close to another person 0 1 2 3 4 
89. Feelings of guilt 0 1 2 3 4 
90. The idea that something is wrong with your mind 0 1 2 3 4 
 
  120 
 
  121 
 
  122 
BIOGRAPHY OF THE AUTHOR 
 Hira Shrestha was born and raised in Bhojpur, a small village in the hills of 
eastern Nepal. Her family migrated to Kathmandu, the capital city of Nepal when she 
was14 years old. She completed her education up to class 10 (School Leaving Certificate; 
SLC) from Vijaya Smarak High School in Dillibazar, Kathmandu, Nepal in 1993, and an 
Intermediate of Arts (2 years) degree with English concentration in 1995 from Kanya 
Multiple College of Dillibazar, an affiliated campus of Tribhuwan University, Nepal. She 
completed her Bachelor’s of Arts (3 years) degree in English Literature with Culture and 
Sociology minor in 2003. Hira was a teacher in several private high schools as well as a 
non-academic English language instructor during her stay in Kathmandu until she 
decided to pursue her second Bachelor’s degree in Psychology with Clinical Mental 
Health track (MHRT- Certified) from Husson University, Bangor, Maine in the Fall of 
2006. She graduated Magna Cum Laude in December 2009, completed her practicum 
internship at the Acadia Hospital in Bangor under the supervision of Dr. David Prescott, 
and then joined the Bangor branch of the Developmental Neuroscience Lab of the 
University of Maine under the leadership of Professor Marie Hayes who is also Hira’s 
mentor and advisor. Hira started her graduate degree in Developmental Psychology with 
Professor Hayes in the Fall of 2011 after a short visit to her family in Nepal. She is a 
candidate for the Master of Arts degree in Developmental Psychology from The 
University of Maine in August 2014. 
 
 
 
